

| | | | | | | | | | | | | |
|---|------------------------------------|---|----------------------------------|-----------|------------------|------------------------------------|-----------|-----------|-------------------------|-----------------|------------------------------------|---|
| <p>(51) International Patent Classification: C12N 15/31, 1/21, C12P 21/02, C07K 14/33, A61K 38/16, 39/08</p> | <p>A1</p> | <p>(11) International Publication Number: WO 98/07864</p> <p>(43) International Publication Date: 26 February 1998 (26.02.98)</p> | | | | | | | | | | |
| <p>(21) International Application Number: PCT/GB97/02273</p> <p>(22) International Filing Date: 22 August 1997 (22.08.97)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>9617671.4</td> <td>23 August 1996 (23.08.96)</td> <td>GB</td> </tr> <tr> <td>9625996.5</td> <td>13 December 1996 (13.12.96)</td> <td>GB</td> </tr> </table> <p>(60) Parent Application or Grant</p> <p>(63) Related by Continuation</p> <table border="0"> <tr> <td>US</td> <td>08/782,893 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>27 December 1996 (27.12.96)</td> </tr> </table> | | 9617671.4 | 23 August 1996 (23.08.96) | GB | 9625996.5 | 13 December 1996 (13.12.96) | GB | US | 08/782,893 (CIP) | Filed on | 27 December 1996 (27.12.96) | <p>Conrad, Padraig [GB/GB]; Microbiological Research Authority CAMR (Centre for Applied Microbiology & Research), Porton Down, Salisbury, Wiltshire SP4 0JG (GB). FOSTER, Keith, Alan [GB/GB]; Microbiological Research Authority CAMR (Centre for Applied Microbiology & Research), Porton Down, Salisbury, Wiltshire SP4 0JG (GB).</p> <p>(74) Agent: SCHLICH, George, William; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).</p> |
| 9617671.4 | 23 August 1996 (23.08.96) | GB | | | | | | | | | | |
| 9625996.5 | 13 December 1996 (13.12.96) | GB | | | | | | | | | | |
| US | 08/782,893 (CIP) | | | | | | | | | | | |
| Filed on | 27 December 1996 (27.12.96) | | | | | | | | | | | |
| <p>(71) Applicants (for all designated States except US): MICROBIOLOGICAL RESEARCH AUTHORITY CAMR (CENTRE FOR APPLIED MICROBIOLOGY & RESEARCH) [GB/GB]; Porton Down, Salisbury, Wiltshire SP4 0JG (GB). THE SPEYWOOD LABORATORY LIMITED [GB/GB]; 14 Kensington Square, London W8 5HH (GB).</p> | | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> | | | | | | | | | | |
| <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SHONE, Clifford, Charles [GB/GB]; Microbiological Research Authority CAMR (Centre for Applied Microbiology & Research), Porton Down, Salisbury, Wiltshire SP4 0JG (GB). QUINN,</p> | | <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | | | | | | | | | | |

• A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TC | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

RECOMBINANT TOXIN FRAGMENTS

This invention relates to recombinant toxin fragments, to DNA encoding these fragments and to their uses such as in a vaccine and for *in vitro* and *in vivo* purposes.

The clostridial neurotoxins are potent inhibitors of calcium-dependent neurotransmitter secretion in neuronal cells. They are currently considered to mediate this activity through a specific endoproteolytic cleavage of at least one of three vesicle or pre-synaptic membrane associated proteins VAMP, syntaxin or SNAP-25 which are central to the vesicle docking and membrane fusion events of neurotransmitter secretion. The neuronal cell targeting of tetanus and botulinum neurotoxins is considered to be a receptor mediated event following which the toxins become internalised and subsequently traffic to the appropriate intracellular compartment where they effect their endopeptidase activity.

The clostridial neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 100 kDa). The HC polypeptide is considered to comprise all or part of two distinct functional domains. The carboxy-terminal half of the HC (ca 50 kDa), termed the H_C domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-terminal half, termed the H_N domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular membranes such that the functional activity of the LC is expressed within the target cell. The H_N domain also has the property, under conditions of low pH, of forming ion-permeable channels in lipid membranes, this may in some manner relate to its translocation function.

For botulinum neurotoxin type A (BoNT/A) these domains are considered to reside within amino acid residues 872-1296 for the H_C, amino acid residues 449-871 for the H_N and residues 1-448 for the LC. Digestion with trypsin effectively degrades the H_C domain of the BoNT/A to generate a non-toxic fragment designated LH_N.

which is no longer able to bind to and enter neurons (Fig. 1). The LH_N fragment so produced also has the property of enhanced solubility compared to both the parent holotoxin and the isolated LC.

It is therefore possible to provide functional definitions of the domains within the neurotoxin molecule, as follows:

(A) clostridial neurotoxin light chain:

-a metalloprotease exhibiting high substrate specificity for vesicle and/or plasma - membrane associated proteins involved in the exocytotic process. In particular, it cleaves one or more of SNAP-25, VAMP (synaptobrevin / cellubrevin) and syntaxin.

(B) clostridial neurotoxin heavy chain H_N domain:

-a portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell.

-the domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell.

-the domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH.

-the domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone.

(C) clostridial neurotoxin heavy chain H_C domain.

-a portion of the heavy chain which is responsible for binding of the native

holotoxin to cell surface receptor(s) involved in the intoxicating action of clostridial toxin prior to internalisation of the toxin into the cell.

The identity of the cellular recognition markers for these toxins is currently not understood and no specific receptor species have yet been identified although Kozaki et al. have reported that synaptotagmin may be the receptor for botulinum neurotoxin type B. It is probable that each of the neurotoxins has a different receptor.

It is desirable to have positive controls for toxin assays, to develop clostridial toxin vaccines and to develop therapeutic agents incorporating desirable properties of clostridial toxin.

However, due to its extreme toxicity, the handling of native toxin is hazardous.

The present invention seeks to overcome or at least ameliorate problems associated with production and handling of clostridial toxin.

Accordingly, the invention provides a polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to neuronal exocytosis and wherein said second domain is adapted (i) to translocate the polypeptide into the cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into the cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of any clostridial neurotoxin precursor that can be converted into toxin by proteolytic action. Accordingly, the invention may thus provide a single polypeptide chain containing a domain equivalent to a clostridial toxin light chain and a domain providing the functional aspects of the H_N of a clostridial toxin heavy chain, whilst lacking the functional aspects of a clostridial toxin H_C domain.

For the purposes of the invention, the functional property or properties of the H_N of a clostridial toxin heavy chain that are required to be exhibited by the second domain of the polypeptide of the invention are either (i) translocation of the polypeptide into a cell, or (ii) increasing solubility of the polypeptide compared to solubility of the first domain on its own or (iii) both (i) and (ii). References hereafter to a H_N domain or to the functions of a H_N domain are references to this property or properties. The second domain is not required to exhibit other properties of the H_N domain of a clostridial toxin heavy chain.

A polypeptide of the invention can thus be soluble but lack the translocation function of a native toxin-this is of use in providing an immunogen for vaccinating or assisting to vaccinate an individual against challenge by toxin. In a specific embodiment of the invention described in an example below a polypeptide designated LH₄₂₃/A elicited neutralising antibodies against type A neurotoxin. A polypeptide of the invention can likewise thus be relatively insoluble but retain the translocation function of a native toxin - this is of use if solubility is imparted to a composition made up of that polypeptide and one or more other components by one or more of said other components.

The first domain of the polypeptide of the invention cleaves one or more vesicle or plasma-membrane associated proteins essential to the specific cellular process of exocytosis, and cleavage of these proteins results in inhibition of exocytosis, typically in a non-cytotoxic manner. The cell or cells affected are not restricted to a particular type or subgroup but can include both neuronal and non-neuronal cells. The activity of clostridial neurotoxins in inhibiting exocytosis has, indeed, been observed almost universally in eukaryotic cells expressing a relevant cell surface receptor, including such diverse cells as from *Aplysia* (sea slug), *Drosophila* (fruit fly) and mammalian nerve cells, and the activity of the first domain is to be understood as including a corresponding range of cells.

The polypeptide of the invention may be obtained by expression of a recombinant nucleic acid, preferably a DNA, and is a single polypeptide, that is to say not

cleaved into separate light and heavy chain domains. The polypeptide is thus available in convenient and large quantities using recombinant techniques.

In a polypeptide according to the invention, said first domain preferably comprises a clostridial toxin light chain or a fragment or variant of a clostridial toxin light chain. The fragment is optionally an N-terminal, or C-terminal fragment of the light chain, or is an internal fragment, so long as it substantially retains the ability to cleave the vesicle or plasma-membrane associated protein essential to exocytosis. The minimal domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem., Vol.267, No. 21, July 1992, pages 14721-14729. The variant has a different peptide sequence from the light chain or from the fragment, though it too is capable of cleaving the vesicle or plasma-membrane associated protein. It is conveniently obtained by insertion, deletion and/or substitution of a light chain or fragment thereof. In embodiments of the invention described below a variant sequence comprises (i) an N-terminal extension to a clostridial toxin light chain or fragment (ii) a clostridial toxin light chain or fragment modified by alteration of at least one amino acid (iii) a C-terminal extension to a clostridial toxin light chain or fragment, or (iv) combinations of 2 or more of (i)-(iii).

In further embodiments of the invention, the variant contains an amino acid sequence modified so that (a) there is no protease sensitive region between the LC and H_N components of the polypeptide, or (b) the protease sensitive region is specific for a particular protease. This latter embodiment is of use if it is desired to activate the endopeptidase activity of the light chain in a particular environment or cell. Though, in general, the polypeptides of the invention are activated prior to administration.

The first domain preferably exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin. The clostridial toxin is preferably botulinum toxin or tetanus toxin.

In an embodiment of the invention described in an example below, the toxin light

chain and the portion of the toxin heavy chain are of botulinum toxin type A. In a further embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type B. The polypeptide optionally comprises a light chain or fragment or variant of one toxin type and a heavy chain or fragment or variant of another toxin type.

In a polypeptide according to the invention said second domain preferably comprises a clostridial toxin heavy chain H_N portion or a fragment or variant of a clostridial toxin heavy chain H_N portion. The fragment is optionally an N-terminal or C-terminal or internal fragment, so long as it retains the function of the H_N domain. Teachings of regions within the H_N responsible for its function are provided for example in Biochemistry 1995, 34, pages 15175-15181 and Eur. J. Biochem, 1989, 185, pages 197-203. The variant has a different sequence from the H_N domain or fragment, though it too retains the function of the H_N domain. It is conveniently obtained by insertion, deletion and/or substitution of a H_N domain or fragment thereof. In embodiments of the invention, described below, it comprises (i) an N-terminal extension to a H_N domain or fragment, (ii) a C-terminal extension to a H_N domain or fragment, (iii) a modification to a H_N domain or fragment by alteration of at least one amino acid, or (iv) combinations of 2 or more of (i)-(iii). The clostridial toxin is preferably botulinum toxin or tetanus toxin.

The invention also provides a polypeptide comprising a clostridial neurotoxin light chain and a N-terminal fragment of a clostridial neurotoxin heavy chain, the fragment preferably comprising at least 423 of the N-terminal amino acids of the heavy chain of botulinum toxin type A, 417 of the N-terminal amino acids of the heavy chain of botulinum toxin type B or the equivalent number of N-terminal amino acids of the heavy chain of other types of clostridial toxin such that the fragment possesses an equivalent alignment of homologous amino acid residues.

These polypeptides of the invention are thus not composed of two or more polypeptides, linked for example by di-sulphide bridges into composite molecules. Instead, these polypeptides are single chains and are not active or their activity is

significantly reduced in an *in vitro* assay of neurotoxin endopeptidase activity.

Further, the polypeptides may be susceptible to be converted into a form exhibiting endopeptidase activity by the action of a proteolytic agent, such as trypsin. In this way it is possible to control the endopeptidase activity of the toxin light chain.

In a specific embodiment of the invention described in an example below, there is provided a polypeptide lacking a portion designated H_C of a clostridial toxin heavy chain. This portion, seen in the naturally produced toxin, is responsible for binding of toxin to cell surface receptors prior to internalisation of the toxin. This specific embodiment is therefore adapted so that it can not be converted into active toxin, for example by the action of a proteolytic enzyme. The invention thus also provides a polypeptide comprising a clostridial toxin light chain and a fragment of a clostridial toxin heavy chain, said fragment being not capable of binding to those cell surface receptors involved in the intoxicating action of clostridial toxin, and it is preferred that such a polypeptide lacks an intact portion designated H_C of a clostridial toxin heavy chain.

In further embodiments of the invention there are provided compositions containing a polypeptide comprising a clostridial toxin light chain and a portion designated H_N of a clostridial toxin heavy chain, and wherein the composition is free of clostridial toxin and free of any clostridial toxin precursor that may be converted into clostridial toxin by the action of a proteolytic enzyme. Examples of these compositions include those containing toxin light chain and H_N sequences of botulinum toxin types A, B, C₁, D, E, F and G.

The polypeptides of the invention are conveniently adapted to bind to, or include, a ligand for targeting to desired cells. The polypeptide optionally comprises a sequence that binds to, for example, an immunoglobulin. A suitable sequence is a tandem repeat synthetic IgG binding domain derived from domain B of Staphylococcal protein A. Choice of immunoglobulin specificity then determines the target for a polypeptide - immunoglobulin complex. Alternatively, the

polypeptide comprises a non-clostridial sequence that binds to a cell surface receptor, suitable sequences including insulin-like growth factor-1 (IGF-1) which binds to its specific receptor on particular cell types and the 14 amino acid residue sequence from the carboxy-terminus of cholera toxin A subunit which is able to bind the cholera toxin B subunit and thence to GM1 gangliosides. A polypeptide according to the invention thus, optionally, further comprises a third domain adapted for binding of the polypeptide to a cell.

In a second aspect the invention provides a fusion protein comprising a fusion of (a) a polypeptide of the invention as described above with (b) a second polypeptide adapted for binding to a chromatography matrix so as to enable purification of the fusion protein using said chromatography matrix. It is convenient for the second polypeptide to be adapted to bind to an affinity matrix, such as a glutathione Sepharose, enabling rapid separation and purification of the fusion protein from an impure source, such as a cell extract or supernatant.

One possible second purification polypeptide is glutathione-S-transferase (GST), and others will be apparent to a person of skill in the art, being chosen so as to enable purification on a chromatography column according to conventional techniques.

As noted above, by proteolytic treatment, for example using trypsin, of a polypeptide of the invention it is possible to induce endopeptidase activity in the treated polypeptide. A third aspect of the invention provides a composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the clostridial toxin, said derivative further being non-toxic *in vivo* due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic *in vivo*. The activity of the derivative preferably approaches that of natural toxin, and is thus preferably at least 30% and most preferably at least 60% of natural toxin. The overall endopeptidase activity of the composition will, of course, also be determined by the amount of the derivative that is present.

While it is known to treat naturally produced clostridial toxin to remove the H_C domain, this treatment does not totally remove toxicity of the preparation, instead some residual toxin activity remains. Natural toxin treated in this way is therefore still not entirely safe. The composition of the invention, derived by treatment of a pure source of polypeptide advantageously is free of toxicity, and can conveniently be used as a positive control in a toxin assay, as a vaccine against clostridial toxin or for other purposes where it is essential that there is no residual toxicity in the composition.

The invention enables production of the polypeptides and fusion proteins of the invention by recombinant means.

A fourth aspect of the invention provides a nucleic acid encoding a polypeptide or a fusion protein according to any of the aspects of the invention described above.

In one embodiment of this aspect of the invention, a DNA sequence provided to code for the polypeptide or fusion protein is not derived from native clostridial sequences, but is an artificially derived sequence not preexisting in nature.

A specific DNA (SEQ ID NO: 1) described in more detail below encodes a polypeptide or a fusion protein comprising nucleotides encoding residues 1-871 of a botulinum toxin type A. Said polypeptide comprises the light chain domain and the first 423 amino acid residues of the amino terminal portion of a botulinum toxin type A heavy chain. This recombinant product is designated LH₄₂₃/A (SEQ ID NO: 2).

In a second embodiment of this aspect of the invention a DNA sequence which codes for the polypeptide or fusion protein is derived from native clostridial sequences but codes for a polypeptide or fusion protein not found in nature.

A specific DNA (SEQ ID NO: 19) described in more detail below encodes a polypeptide or a fusion protein and comprises nucleotides encoding residues 1-

1171 of a botulinum toxin type B. Said polypeptide comprises the light chain domain and the first 728 amino acid residues of the amino terminal protein of a botulinum type B heavy chain. This recombinant product is designated LH₇₂₈/B (SEQ ID NO: 20).

The invention thus also provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA according to the third aspect of the invention. The host cell is suitably not able to cleave a polypeptide or fusion protein of the invention so as to separate light and heavy toxin chains; for example, a non-clostridial host.

The invention further provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA encoding a fusion protein as described above, purifying the fusion protein by elution through a chromatography column adapted to retain the fusion protein, eluting through said chromatography column a ligand adapted to displace the fusion protein and recovering the fusion protein. Production of substantially pure fusion protein is thus made possible. Likewise, the fusion protein is readily cleaved to yield a polypeptide of the invention, again in substantially pure form, as the second polypeptide may conveniently be removed using the same type of chromatography column.

The LH_N/A derived from dichain native toxin requires extended digestion with trypsin to remove the C-terminal 1/2 of the heavy chain, the H_C domain. The loss of this domain effectively renders the toxin inactive *in vivo* by preventing its interaction with host target cells. There is, however, a residual toxic activity which may indicate a contaminating, trypsin insensitive, form of the whole type A neurotoxin.

In contrast, the recombinant preparations of the invention are the product of a discreet, defined gene coding sequence and can not be contaminated by full length toxin protein. Furthermore, the product as recovered from *E. coli*, and from other recombinant expression hosts, is an inactive single chain peptide or if expression

hosts produce a processed, active polypeptide it is not a toxin. Endopeptidase activity of LH₄₂₃/A, as assessed by the current *in vitro* peptide cleavage assay, is wholly dependent on activation of the recombinant molecule between residues 430 and 454 by trypsin. Other proteolytic enzymes that cleave between these two residues are generally also suitable for activation of the recombinant molecule. Trypsin cleaves the peptide bond C-terminal to Arginine or C-terminal to Lysine and is suitable as these residues are found in the 430-454 region and are exposed (see Fig. 12).

The recombinant polypeptides of the invention are potential therapeutic agents for targeting to cells expressing the relevant substrate but which are not implicated in effecting botulism. An example might be where secretion of neurotransmitter is inappropriate or undesirable or alternatively where a neuronal cell is hyperactive in terms of regulated secretion of substances other than neurotransmitter. In such an example the function of the H_C domain of the native toxin could be replaced by an alternative targeting sequence providing, for example, a cell receptor ligand and/or translocation domain.

One application of the recombinant polypeptides of the invention will be as a reagent component for synthesis of therapeutic molecules, such as disclosed in WO-A-94/21300. The recombinant product will also find application as a non-toxic standard for the assessment and development of *in vitro* assays for detection of functional botulinum or tetanus neurotoxins either in foodstuffs or in environmental samples, for example as disclosed in EP-A-0763131.

A further option is addition, to the C-terminal end of a polypeptide of the invention, of a peptide sequence which allows specific chemical conjugation to targeting ligands of both protein and non-protein origin.

In yet a further embodiment an alternative targeting ligand is added to the N-terminus of polypeptides of the invention. Recombinant LH_N derivatives have been designated that have specific protease cleavage sites engineered at the C-terminus

of the LC at the putative trypsin sensitive region and also at the extreme C-terminus of the complete protein product. These sites will enhance the activational specificity of the recombinant product such that the dichain species can only be activated by proteolytic cleavage of a more predictable nature than use of trypsin.

The LH_N enzymatically produced from native BoNT/A is an efficient immunogen and thus the recombinant form with its total divorce from any full length neurotoxin represents a vaccine component. The recombinant product may serve as a basal reagent for creating defined protein modifications in support of any of the above areas.

Recombinant constructs are assigned distinguishing names on the basis of their amino acid sequence length and their Light Chain (L-chain, L) and Heavy Chain (H-chain, H) content as these relate to translated DNA sequences in the public domain or specifically to SEQ ID NO: 2 and SEQ ID NO: 20. The 'LH' designation is followed by '/X' where 'X' denotes the corresponding clostridial toxin serotyp or class, e.g. 'A' for botulinum neurotoxin type A or 'TeTx' for tetanus toxin. Sequence variants from that of the native toxin polypeptide are given in parenthesis in standard format, namely the residue position number prefixed by the residue of the native sequence and suffixed by the residue of the variant.

Subscript number prefixes indicate an amino-terminal (N-terminal) extension, or where negative a deletion, to the translated sequence. Similarly, subscript number suffixes indicate a carboxy terminal (C-terminal) extension or where negative numbers are used, a deletion. Specific sequence inserts such as protease cleavage sites are indicated using abbreviations, e.g. Factor Xa is abbreviated to FXa. L-chain C-terminal suffixes and H-chain N-terminal prefixes are separated by a '/' to indicate the predicted junction between the L and H-chains. Abbreviations for engineered ligand sequences are prefixed or suffixed to the clostridial L-chain or H-chain corresponding to their position in the translation product.

Following this nomenclature,

- LH₄₂₃/A = SEQ ID NO: 2, containing the entire L-chain and 423 amino acids of the H-chain of botulinum neurotoxin type A;
- ₂LH₄₂₃/A = a variant of this molecule, containing a two amino acid extension to the N-terminus of the L-chain;
- ₂L_{1/2}H₄₂₃/A = a further variant in which the molecule contains a two amino acid extension on the N-terminus of both the L-chain and the H-chain;
- ₂L_{FXa/2}H₄₂₃/A = a further variant containing a two amino acid extension to the N-terminus of the L-chain, and a Factor Xa cleavage sequence at the C-terminus of the L-chain which, after cleavage of the molecule with Factor Xa leaves a two amino acid N-terminal extension to the H-chain component; and
- ₂L_{FXa/2}H₄₂₃/A-IGF-1 = a variant of this molecule which has a further C-terminal extension to the H-chain, in this example the insulin-like growth factor 1 (IGF-1) sequence.

There now follows description of specific embodiments of the invention, illustrated by drawings in which:

Fig. 1 shows a schematic representation of the domain structure of botulinum neurotoxin type A (BoNT/A);

Fig. 2 shows a schematic representation of assembly of the gene for an embodiment of the invention designated LH₄₂₃/A;

- Fig. 3 is a graph comparing activity of native toxin, trypsin generated "native" LH_N/A and an embodiment of the invention designated ${}_2LH_{423}/A$ ($Q_2E,N_{26}K,A_{27}Y$) in an *in vitro* peptide cleavage assay;
- Fig. 4 is a comparison of the first 33 amino acids in published sequences of native toxin and embodiments of the invention;
- Fig. 5 shows the transition region of an embodiment of the invention designated $L/{}_4H_{423}/A$ illustrating insertion of four amino acids at the N-terminus of the H_N sequence; amino acids coded for by the *Eco* 47 III restriction endonuclease cleavage site are marked and the H_N sequence then begins ALN...;
- Fig. 6 shows the transition-region of an embodiment of the invention designated $L_{FXa/3}H_{423}/A$ illustrating insertion of a Factor Xa cleavage site at the C-terminus of the L-chain, and three additional amino acids coded for at the N-terminus of the H-sequence; the N-terminal amino acid of the cleavage-activated H_N will be cysteine;
- Fig. 7 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated $L_{FXa/3}H_{423}/A$ -IGF-1, a fusion protein; the IGF-1 sequence begins at position G_{882} ;
- Fig. 8 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated $L_{FXa/3}H_{423}/A$ -CtxA14, a fusion protein; the C-terminal CtxA sequence begins at position Q_{882} ;
- Fig.9 shows the C-terminal portion of the amino acid sequence of an

embodiment of the invention designated $L_{FX8/3}H_{423}/A-ZZ$, a fusion protein; the C-terminal ZZ sequence begins at position A_{890} immediately after a genenase recognition site (underlined);

show schematic representations of manipulations of

Figs. 10 & 11 polypeptides of the invention; Fig. 10 shows LH_{423}/A with N-terminal addition of an affinity purification peptide (in this case GST) and C-terminal addition of an Ig binding domain; protease cleavage sites R1, R2 and R3 enable selective enzymatic separation of domains; Fig. 11 shows specific examples of protease cleavage sites R1, R2 and R3 and a C-terminal fusion peptide sequence;

Fig. 12 shows the trypsin sensitive activation region of a polypeptide of the invention;

Fig. 13 shows Western blot analysis of recombinant LH_{107}/B expressed from *E.coli*; panel A was probed with anti-BoNT/B antiserum; Lane 1, molecular weight standards; lanes 2 & 3, native BoNT/B; lane 4, immunopurified LH_{107}/B ; panel B was probed with anti-T7 peptid tag antiserum; lane 1, molecular weight standards; lanes 2 & 3, positive control *E.coli* T7 expression; lan 4 immunopurified LH_{107}/B .

The sequence listing that accompanies this application contains the following sequences:-

SEQ ID NO:

1

Sequence

DNA coding for LH_{423}/A

- 2 LH₄₂₃/A
- 3 DNA coding for ₂₃LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y), of which an
N-terminal portion is shown in Fig. 4.
- 4 ₂₃LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y)
- 5 DNA coding for ₂LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y), of which an N-
terminal portion is shown in Fig.4
- 6 ₂LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y)
- 7 DNA coding for native BoNT/A according to Binz et al
- 8 native BoNT/A according to Binz et al
- 9 DNA coding for L₁₄H₄₂₃/A
- 10 L₁₄H₄₂₃/A
- 11 DNA coding for L_{FXa/3}H₄₂₃/A
- 12 L_{FXa/3}H₄₂₃/A
- 13 DNA coding for L_{FXa/3}H₄₂₃/A-IGF-1
- 14 L_{FXa/3}H₄₂₃/A-IGF-1
- 15 DNA coding for L_{FXa/3}H₄₂₃/A-CtxA14
- 16 L_{FXa/3}H₄₂₃/A-CtxA14
- 17 DNA coding for L_{FXa/3}H₄₂₃/A-ZZ
- 18 L_{FXa/3}H₄₂₃/A-ZZ
- 19 DNA coding for LH₇₂₈/B
- 20 LH₇₂₈/B
- 21 DNA coding for LH₄₁₇/B
- 22 LH₄₁₇/B
- 23 DNA coding for LH₁₀₇/B
- 24 LH₁₀₇/B
- 25 DNA coding for LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y)
- 26 LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y)
- 27 DNA coding for LH₄₁₇/B wherein the first 274 bases are

modified to have an *E.coli* codon bias

28 DNA coding for LH₄₁₇/B wherein bases 691-1641 of the native BoNT/B sequence have been replaced by a degenerate DNA coding for amino acid residues 231-547 of the native BoNT/B polypeptide

Example 1

A 2616 base pair, double stranded gene sequence (SEQ ID NO: 1) has been assembled from a combination of synthetic, chromosomal and polymerase-chain-reaction generated DNA (Figure 2). The gene codes for a polypeptide of 871 amino acid residues corresponding to the entire light-chain (LC, 448 amino acids) and 423 residues of the amino terminus of the heavy-chain (H_C) of botulinum neurotoxin type A. This recombinant product is designated the LH₄₂₃/A fragment (SEQ ID NO: 2).

Construction of the recombinant product

The first 918 base pairs of the recombinant gene were synthesised by concatenation of short oligonucleotides to generate a coding sequence with an *E. coli* codon bias. Both DNA strands in this region were completely synthesised as short overlapping oligonucleotides which were phosphorylated, annealed and ligated to generate the full synthetic region ending with a unique *KpnI* restriction site. The remainder of the LH₄₂₃/A coding sequence was PCR amplified from total chromosomal DNA from *Clostridium botulinum* and annealed to the synthetic portion of the gene.

The internal PCR amplified product sequences were then deleted and replaced with the native, fully sequenced, regions from clones of *C. botulinum* chromosomal origin to generate the final gene construct. The final composition is synthetic DNA (bases 1-913), polymerase amplified DNA (bases 914-1138 and 1976-2616) and the remainder is of *C. botulinum* chromosomal origin (bases 1139-1975). The

assembled gen was then fully sequenced and cloned into a variety of *E.coli* plasmid vectors for expression analysis.

Expression of the recombinant gene and recovery of protein product

The DNA is expressed in *E. coli* as a single nucleic acid transcript producing a soluble single chain polypeptide of 99,951 Daltons predicted molecular weight. The gene is currently expressed in *E. coli* as a fusion to the commercially available coding sequence of glutathione S-transferase (GST) of *Schistosoma japonicum* but any of an extensive range of recombinant gene expression vectors such as pEZZ18, pTrc99, pFLAG or the pMAL series may be equally effective as might expression in other prokaryotic or eukaryotic hosts such as the Gram positive bacilli, the yeast *P. pastoris* or in insect or mammalian cells under appropriate conditions.

Currently, *E. coli* harbouring the expression construct is grown in Luria-Bertani broth (L-broth pH 7.0, containing 10 g/l bacto-tryptone, 5 g/l bacto-yeast extract and 10 g/l sodium chloride) at 37° C until the cell density (biomass) has an optical absorbance of 0.4- 0.6 at 600 nm and the cells are in mid-logarithmic growth phase. Expression of the gene is then induced by addition of isopropylthio- β -D-galactosidase (IPTG) to a final concentration of 0.5 mM. Recombinant gene expression is allowed to proceed for 90 min at a reduced temperature of 25°C. The cells are then harvested by centrifugation, are resuspended in a buffer solution containing 10 mM Na₂HPO₄, 0.5 M NaCl, 10 mM EGTA, 0.25% Tween, pH 7.0 and then frozen at -20°C. For extraction of the recombinant protein the cells are disrupted by sonication. The cell extract is then cleared of debris by centrifugation and the cleared supernatant fluid containing soluble recombinant fusion protein (GST- LH₄₂₃/A) is stored at -20°C pending purification. A proportion of recombinant material is not released by the sonication procedure and this probably reflects insolubility or inclusion body formation. Currently we do not extract this material for analysis but if desired this could be readily achieved using methods known to those skilled in the art.

The recombinant GST- LH₄₂₃/A is purified by adsorption onto a commercially prepared affinity matrix of glutathione Sepharose and subsequent elution with reduced glutathione. The GST affinity purification marker is then removed by proteolytic cleavage and reabsorption to glutathione Sepharose; recombinant LH₄₂₃/A is recovered in the non-adsorbed material.

Construct variants

A variant of the molecule, LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y) (SEQ ID NO: 26) has been produced in which three amino acid residues have been modified within the light chain of LH₄₂₃/A producing a polypeptide containing a light chain sequence different to that of the published amino acid sequence of the light chain of BoNT/A.

Two further variants of the gene sequence that have been expressed and the corresponding products purified are ₂₃LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y) (SEQ ID NO: 4) which has a 23 amino acid N-terminal extension as compared to the predicted native L-chain of BoNT/A and ₂LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y) (SEQ ID NO: 6) which has a 2 amino acid N-terminal extension (Figure 4).

In yet another variant a gene has been produced which contains a *Eco* 47 III restriction site between nucleotides 1344 and 1345 of the gene sequence given in (SEQ ID NO: 1). This modification provides a restriction site at the position in the gene representing the interface of the heavy and light chains in native neurotoxin, and provides the capability to make insertions at this point using standard restriction enzyme methodologies known to those skilled in the art. It will also be obvious to those skilled in the art that any one of a number of restriction sites could be so employed, and that the *Eco* 47 III insertion simply exemplifies this approach. Similarly, it would be obvious for one skilled in the art that insertion of a restriction site in the manner described could be performed on any gene of the invention. The gene described, when expressed, codes for a polypeptide, L₁₄H₄₂₃/A (SEQ ID NO: 10), which contains an additional four amino acids between amino acids 448 and 449 of LH₄₂₃/A at a position equivalent to the amino terminus of the

heavy chain of native BoNT/A.

A variant of the gene has been expressed, $L_{FXa/3}H_{423}/A$ (SEQ ID NO: 12), in which a specific proteolytic cleavage site was incorporated at the carboxy-terminal end of the light chain domain, specifically after residue 448 of $L_{14}H_{423}/A$. The cleavage site incorporated was for Factor Xa protease and was coded for by modification of SEQ ID NO: 1. It will be apparent to one skilled in the art that a cleavage site for another specified protease could be similarly incorporated, and that any gene sequence coding for the required cleavage site could be employed. Modification of the gene sequence in this manner to code for a defined protease site could be performed on any gene of the invention.

Variants of $L_{FXa/3}H_{423}/A$ have been constructed in which a third domain is present at the carboxy-terminal end of the polypeptide which incorporates a specific binding activity into the polypeptide.

Specific examples described are:

- (1) $L_{FXa/3}H_{423}/A$ -IGF-1 (SEQ ID NO: 14) , in which the carboxy-terminal domain has a sequence equivalent to that of insulin-like growth factor-1 (IGF-1) and is able to bind to the insulin-like growth factor receptor with high affinity;
- (2) $L_{FXa/3}H_{423}/A$ -CtxA14 (SEQ ID NO: 16) , in which the carboxy-terminal domain has a sequence equivalent to that of the 14 amino acids from the carboxy-terminus of the A-subunit of cholera toxin (CtxA) and is thereby able to interact with the cholera toxin B-subunit pentamer; and
- (3) $L_{FXa/3}H_{423}/A$ -ZZ (SEQ ID NO: 18) , in which the carboxy-terminal domain is a tandem repeating synthetic IgG binding domain. This variant also exemplifies another modification applicable to the current invention, namely the inclusion in the gene of a sequence coding for a protease cleavage site located between the end of the clostridial heavy chain sequence and the sequence coding for the binding

ligand. Specifically in this example a sequence is inserted at nucleotides 2650 to 2666 coding for a genenase cleavage site. Expression of this gene produces a polypeptide which has the desired protease sensitivity at the interface between the domain providing H_N function and the binding domain. Such a modification enables selective removal of the C-terminal binding domain by treatment of the polypeptide with the relevant protease.

It will be apparent that any one of a number of such binding domains could be incorporated into the polypeptide sequences of this invention and that the above examples are merely to exemplify the concept. Similarly, such binding domains can be incorporated into any of the polypeptide sequences that are the basis of this invention. Further, it should be noted that such binding domains could be incorporated at any appropriate location within the polypeptide molecules of the invention.

Further embodiments of the invention are thus illustrated by a DNA of the invention further comprising a desired restriction endonuclease site at a desired location and by a polypeptide of the invention further comprising a desired protease cleavage site at a desired location.

The restriction endonuclease site may be introduced so as to facilitate further manipulation of the DNA in manufacture of an expression vector for expressing a polypeptide of the invention; it may be introduced as a consequence of a previous step in manufacture of the DNA; it may be introduced by way of modification by insertion, substitution or deletion of a known sequence. The consequence of modification of the DNA may be that the amino acid sequence is unchanged, or may be that the amino acid sequence is changed, for example resulting in introduction of a desired protease cleavage site, either way the polypeptide retains its first and second domains having the properties required by the invention.

Figure 10 is a diagrammatic representation of an expression product exemplifying features described in this example. Specifically, it illustrates a single polypeptide

incorporating a domain equivalent to the light chain of botulinum neurotoxin type A and a domain equivalent to the H_N domain of the heavy chain of botulinum neurotoxin type A with a N-terminal extension providing an affinity purification domain, namely GST, and a C-terminal extension providing a ligand binding domain, namely an IgG binding domain. The domains of the polypeptide are spatially separated by specific protease cleavage sites enabling selective enzymatic separation of domains as exemplified in the Figure. This concept is more specifically depicted in Figure 11 where the various protease sensitivities are defined for the purpose of example.

Assay of product activity

The LC of botulinum neurotoxin type A exerts a zinc-dependent endopeptidase activity on the synaptic vesicle associated protein SNAP-25 which it cleaves in a specific manner at a single peptide bond. The ₂LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y) (SEQ ID NO: 6) cleaves a synthetic SNAP-25 substrate *in vitro* under the same conditions as the native toxin (Figure 3). Thus, the modification of the polypeptide sequence of ₂LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y) relative to the native sequence and within the minimal functional LC domains does not prevent the functional activity of the LC domains.

This activity is dependent on proteolytic modification of the recombinant GST-₂LH₄₂₃/A (Q₂E,N₂₆K,A₂₇Y) to convert the single chain polypeptide product to a disulphide linked dichain species. This is currently done using the proteolytic enzyme trypsin. The recombinant product (100-600 µg/ml) is incubated at 37°C for 10-50 minutes with trypsin (10 µg/ml) in a solution containing 140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.3. The reaction is terminated by addition of a 100-fold molar excess of trypsin inhibitor. The activation by trypsin generates a disulphide linked dichain species as determined by polyacrylamide gel electrophoresis and immunoblotting analysis using polyclonal anti-botulinum neurotoxin type A antiserum.

₂LH₄₂₃/A is more stable in the presence of trypsin and more active in the *in vitro*

peptide cleavage assay than is ${}_{23}\text{LH}_{423}/\text{A}$. Both variants, however, are fully functional in the *in vitro* peptide cleavage assay. This demonstrates that the recombinant molecule will tolerate N-terminal amino acid extensions and this may be expanded to other chemical or organic moieties as would be obvious to those skilled in the art.

Example 2

As a further exemplification of this invention a number of gene sequences have been assembled coding for polypeptides corresponding to the entire light-chain and varying numbers of residues from the amino terminal end of the heavy chain of botulinum neurotoxin type B. In this exemplification of the disclosure the gene sequences assembled were obtained from a combination of chromosomal and polymerase-chain-reaction generated DNA, and therefore have the nucleotide sequence of the equivalent regions of the natural genes, thus exemplifying the principle that the substance of this disclosure can be based upon natural as well as a synthetic gene sequences.

The gene sequences relating to this example were all assembled and expressed using methodologies as detailed in Sambrook J, Fritsch E F & Maniatis T (1989) *Molecular Cloning: A Laboratory Manual* (2nd Edition), Ford N, Nolan C, Ferguson M & Ockler M (eds), Cold Spring Harbor Laboratory Press, New York, and known to those skilled in the art.

A gene has been assembled coding for a polypeptide of 1171 amino acids corresponding to the entire light-chain (443 amino acids) and 728 residues from the amino terminus of the heavy chain of neurotoxin type B. Expression of this gene produces a polypeptide, LH_{728}/B (SEQ ID NO: 20), which lacks the specific neuronal binding activity of full length BoNT/B.

A gene has also been assembled coding for a variant polypeptide, LH_{417}/B (SEQ ID NO: 22), which possesses an amino acid sequence at its carboxy terminus

equivalent by amino acid homology to that at the carboxy-terminus of the heavy chain fragment in native LH_N/A.

A gene has also been assembled coding for a variant polypeptide, LH₁₀₇/B (SEQ ID NO: 24), which expresses at its carboxy-terminus a short sequence from the amino terminus of the heavy chain of BoNT/B sufficient to maintain solubility of the expressed polypeptide.

Construct Variants

A variant of the coding sequence for the first 274 bases of the gene shown in SEQ ID NO: 21 has been produced which whilst being a non-native nucleotide sequence still codes for the native polypeptide.

Two double stranded, a 268 base pair and a 951 base pair, gene sequences have been created using an overlapping primer PCR strategy. The nucleotide bias of these sequences was designed to have an *E.coli* codon usage bias.

For the first sequence, six oligonucleotides representing the first (5') 268 nucleotides of the native sequence for botulinum toxin type B were synthesised. For the second sequence 23 oligonucleotides representing internal sequence nucleotides 691-1641 of the native sequence for botulinum toxin type B were synthesised. The oligonucleotides ranged from 57-73 nucleotides in length. Overlapping regions, 17-20 nucleotides, were designed to give melting temperatures in the range 52-56°C. In addition, terminal restriction endonuclease sites of the synthetic products were constructed to facilitate insertion of these products into the exact corresponding region of the native sequence. The 268 bp 5' synthetic sequence has been incorporated into the gene shown in SEQ ID NO: 21 in place of the original first 268 bases (and is shown in SEQ ID NO: 27). Similarly the sequence could be inserted into other genes of the examples.

Another variant sequence equivalent to nucleotides 691 to 1641 of SEQ ID NO: 21

, and employing non-native codon usage whilst coding for a native polypeptide sequence, has been constructed using the internal synthetic sequence. This sequence (SEQ ID NO: 28) can be incorporated, alone or in combination with other variant sequences, in place of the equivalent coding sequence in any of the genes of the example.

Example 3

An exemplification of the utility of this invention is as a non-toxic and effective immunogen. The non-toxic nature of the recombinant, single chain material was demonstrated by intraperitoneal administration in mice of GST-₂LH₄₂₃/A. The polypeptide was prepared and purified as described above. The amount of immunoreactive material in the final preparation was determined by enzyme linked immunosorbent assay (ELISA) using a monoclonal antibody (BA11) reactive against a conformation dependent epitope on the native LH_N/A. The recombinant material was serially diluted in phosphate buffered saline (PBS; NaCl 8 g/l, KCl 0.2 g/l, Na₂HPO₄ 1.15 g/l, KH₂PO₄ 0.2 g/l, pH 7.4) and 0.5 ml volumes injected into 3 groups of 4 mice such that each group of mice received 10, 5 and 1 micrograms of material respectively. Mice were observed for 4 days and no deaths were seen.

For immunisation, 20 µg of GST-₂LH₄₂₃/A in a 1.0 ml volume of water-in-oil emulsion (1:1 vol:vol) using Freund's complete (primary injections only) or Freund's incomplete adjuvant was administered into guinea pigs via two sub-cutaneous dorsal injections. Three injections at 10 day intervals were given (day 1, day 10 and day 20) and antiserum collected on day 30. The antisera were shown by ELISA to be immunoreactive against native botulinum neurotoxin type A and to its derivative LH_N/A. Antisera which were botulinum neurotoxin reactive at a dilution of 1:2000 were used for evaluation of neutralising efficacy in mice. For neutralisation assays 0.1 ml of antiserum was diluted into 2.5 ml of gelatine phosphate buffer (GPB; Na₂HPO₄ anhydrous 10 g/l, gelatin (Difco) 2 g/l, pH 6.5-6.6) containing a dilution range from 0.5 µg (5X10⁻⁶ g) to 5 picograms (5X10⁻¹² g). Aliquots of 0.5 ml were injected into mice intraperitoneally and deaths recorded

over a 4 day period. The results are shown in Table 1 and Table 2. It can clearly be seen that 0.5 ml of 1:40 diluted anti- GST-₂LH₄₂₃/A antiserum can protect mice against intraperitoneal challenge with botulinum neurotoxin in the range 5 pg - 50 ng (1 - 10,000 mouse LD50; 1 mouse LD50 = 5 pg).

TABLE 1. Neutralisation of botulinum neurotoxin in mice by guinea pig anti-GST-LH₄₂₃/A antiserum.

| Survivors On Day | <u>Botulinum Toxin/mouse</u> | | | | | | Contr 1 (no toxin) |
|---------------------|------------------------------|---------------|----------------|-------|---------|-----|-----------------------|
| | 0.5 μ g | 0.005 μ g | 0.0005 μ g | 0.5ng | 0.005ng | 5pg | |
| 1 | 0 | 4 | 4 | 4 | 4 | 4 | 4 |
| 2 | - | 4 | 4 | 4 | 4 | 4 | 4 |
| 3 | - | 4 | 4 | 4 | 4 | 4 | 4 |
| 4 | - | 4 | 4 | 4 | 4 | 4 | 4 |

TABLE 2. Neutralisation of botulinum neurotoxin in mice by non-immune guinea pig antiserum.

| Survivors On Day | <u>Botulinum Toxin/mouse</u> | | | | | | Control (no toxin) |
|---------------------|------------------------------|---------------|----------------|-------|---------|-----|-----------------------|
| | 0.5 μ g | 0.005 μ g | 0.0005 μ g | 0.5ng | 0.005ng | 5pg | |
| 1 | 0 | 0 | 0 | 0 | 0 | 2 | 4 |
| 2 | - | - | - | - | - | 0 | 4 |
| 3 | - | - | - | - | - | - | 4 |
| 4 | - | - | - | - | - | - | 4 |

Example 4

Expression of recombinant LH₁₀₇/B in *E. coli*.

As an exemplification of the expression of a nucleic acid coding for a LH_N of a clostridial neurotoxin of a serotype other than botulinum neurotoxin type A, the nucleic acid sequence (SEQ ID NO: 23) coding for the polypeptide LH₁₀₇/B (SEQ ID

NO: 24) was inserted into the commercially available plasmid pET28a (Novogen, Madison, WI, USA). The nucleic acid was expressed in *E. coli* BL21 (DE3) (New England BioLabs, Beverly, MA, USA) as a fusion protein with a N-terminal T7 fusion peptide, under IPTG induction at 1 mM for 90 minutes at 37°C. Cultures were harvested and recombinant protein extracted as described previously for LH₄₂₃/A.

Recombinant protein was recovered and purified from bacterial paste lysates by immunoaffinity adsorption to an immobilised anti-T7 peptide monoclonal antibody using a T7 tag purification kit (New England bioLabs, Beverly, MA, USA). Purified recombinant protein was analysed by gradient (4-20%) denaturing SDS-polyacrylamide gel electrophoresis (Novex, San Diego, CA, USA) and western blotting using polyclonal anti-botulinum neurotoxin type antiserum or anti-T7 antiserum. Western blotting reagents were from Novex, immunostained proteins were visualised using the Enhanced Chemi-Luminescence system (ECL) from Amersham. The expression of an anti-T7-antibody and anti-botulinum neurotoxin type B antiserum reactive recombinant product is demonstrated in Figure 13.

The recombinant product was soluble and retained that part of the light chain responsible for endopeptidase activity.

The invention thus provides recombinant polypeptides useful inter alia as immunogens, enzyme standards and components for synthesis of molecules as described in WO-A-94/21300.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: MICROBIOLOGICAL RESEARCH AUTHORITY
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP): SP4 0JG

(A) NAME: THE SPEYWOOD LABORATORY LIMITED
(B) STREET: 14 Kensington Square
(C) CITY: London
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP): W8 5HH

(A) NAME: FOSTER; Keith Alan
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP): SP4 0JG

(A) NAME: QUINN; Conrad Padraig
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP): SP4 0JG

(A) NAME: SHONE; Clifford Charles
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP): SP4 0JG

(ii) TITLE OF INVENTION: Recombinant Toxin Fragments

(iii) NUMBER OF SEQUENCES: 28

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2616 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..2616

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

| | |
|---|-----|
| ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 | 48 |
| GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20 25 30 | 96 |
| GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45 | 144 |
| GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 | 192 |
| GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 | 240 |
| GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 | 288 |
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 | 336 |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 | 384 |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 | 432 |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 | 480 |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 | 528 |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190 | 576 |
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |

| | |
|---|------|
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 | 1392 |
| AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 | 1440 |
| ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu 485 490 495 | 1488 |
| GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 | 1536 |

| | |
|---|------|
| GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu 515 520 525 | 1584 |
| GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 | 1632 |
| TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu 545 550 555 560 | 1680 |
| CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 | 1728 |
| TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 | 1776 |
| AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA Lys Val Asn Lys Ala Thr Glu Ala Met Phe Leu Gly Trp Val Glu 595 600 605 | 1824 |
| CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 | 1872 |
| GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala 625 630 635 640 | 1920 |
| TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 | 1968 |
| ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala 660 665 670 | 2016 |
| ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys 675 680 685 | 2064 |
| GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 | 2112 |
| AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys 705 710 715 720 | 2160 |
| GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 | 2208 |
| GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn 740 745 750 | 2256 |
| CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp 755 760 765 | 2304 |
| TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile 770 775 780 | 2352 |

- 33 -

| | |
|---|------|
| AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 | 2400 |
| ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 | 2448 |
| GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly 820 825 830 | 2496 |
| CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 | 2544 |
| ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser 850 855 860 | 2592 |
| ACA TTT ACT GAA TAT ATT AAG TAA Thr Phe Thr Glu Tyr Ile Lys * 865 870 | 2616 |

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 872 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

| |
|--|
| Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20 25 30 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45 |
| Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 |
| Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 |
| Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 |
| Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 |
| Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 |
| Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 |
| Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 |
| Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 |

Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
 180 185 190
 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
 195 200 205
 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
 210 215 220
 Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
 225 230 235 240
 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
 245 250 255
 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
 260 265 270
 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
 275 280 285
 Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
 290 295 300
 Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe
 450 455 460
 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu
 465 470 475 480
 Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu
 485 490 495
 Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro
 500 505 510
 Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu
 515 520 525

Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu
 530 535 540
 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu
 545 550 555 560
 His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu
 565 570 575
 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys
 580 585 590
 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
 595 600 605
 Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
 610 615 620
 Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala
 625 630 635 640
 Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu
 645 650 655
 Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala
 660 665 670
 Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys
 675 680 685
 Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu
 690 695 700
 Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys
 705 710 715 720
 Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu
 725 730 735
 Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn
 740 745 750
 Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp
 755 760 765
 Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile
 770 775 780
 Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met
 785 790 795 800
 Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys
 805 810 815
 Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly
 820 825 830
 Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
 835 840 845
 Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
 850 855 860
 Thr Phe Thr Glu Tyr Ile Lys *
 865 870

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2685 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION:1..2685

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

| | |
|---|-----|
| GGA TCC CCA GGA ATT CAT ATG ACG TCG ACG CGT CTG CAG AAG CTT CTA | 48 |
| Gly Ser Pro Gly Ile His Met Thr Ser Thr Arg Leu Gln Lys Leu Leu | |
| 1 5 10 15 | |
| GAA TTC GAG CTC CCG GGT ACC ATG GAG TTC GTG AAC AAG CAG TTC AAC | 96 |
| Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lys Gln Phe Asn | |
| 20 25 30 | |
| TAT AAG GAC CCT GTA AAC GGT GTT GAC ATT GCC TAC ATC AAA ATT CCA | 144 |
| Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro | |
| 35 40 45 | |
| AAG TAC GGC CAG ATG CAG CCG GTG AAG GCT TTC AAG ATT CAT AAC AAA | 192 |
| Lys Tyr Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys | |
| 50 55 60 | |
| ATC TGG GTT ATT CCG GAA CGC GAT ACA TTT ACG AAC CCG GAA GAA GGA | 240 |
| Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly | |
| 65 70 75 80 | |
| GAC TTG AAC CCG CCG CCG GAA GCA AAG CAG GTG CCA GTT TCA TAC TAC | 288 |
| Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr | |
| 85 90 95 | |
| GAT TCA ACC TAT CTG AGC ACA GAC AAC GAG AAG GAT AAC TAC CTG AAG | 336 |
| Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys | |
| 100 105 110 | |
| GGA GTG ACC AAA TTA TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT | 384 |
| Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg | |
| 115 120 125 | |
| ATG CTG CTG ACC TCA ATC GTC CGC GGA ATC CCA TTT TGG GGT GGC AGT | 432 |
| Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser | |
| 130 135 140 | |
| ACC ATT GAC ACG GAG TTG AAG GTT ATT GAC ACT AAC TGC ATT AAC GTG | 480 |
| Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val | |
| 145 150 155 160 | |
| ATC CAA CCA GAC GGT AGC TAC AGA TCT GAA GAA CTT AAC CTC GTA ATC | 528 |
| Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Leu Asn Leu Val Ile | |
| 165 170 175 | |
| ATC GGG CCC TCC GCG GAC ATT ATC CAG TTT GAG TGC AAG AGC TTT GGC | 576 |
| Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly | |
| 180 185 190 | |
| CAC GAA GTG TTG AAC CTG ACG CGT AAC GGT TAC GGC TCT ACT CAG TAC | 624 |
| His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr | |
| 195 200 205 | |

| | |
|---|------|
| ATT CGT TTC AGC CCA GAC TTC ACG TTC GGT TTC GAG GAG AGC CTG GAG Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu 210 215 220 | 672 |
| GTT GAT ACC AAC CCG CTG TTG GGT GCA GGC AAG TTC GCA ACT GAT CCA Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro 225 230 235 240 | 720 |
| GCG GTG ACC CTG GCA CAC GAG CTG ATC CAC GCC GGT CAT CGT CTG TAT Ala Val Thr Leu Ala His Glu Leu Ile His Ala Gly His Arg Leu Tyr 245 250 255 | 768 |
| GGC ATT GCG ATT AAC CCG AAC CGC GTG TTC AAG GTT AAC ACC AAC GCC Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala 260 265 270 | 816 |
| TAC TAC GAG ATG AGT GGT TTA GAA GTA AGC TTC GAG GAA CTG CGC ACG Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr 275 280 285 | 864 |
| TTC GGT GGC CAT GAT GCG AAG TTT ATC GAC AGC TTG CAG GAG AAC GAG Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu 290 295 300 | 912 |
| TTC CGT CTG TAC TAC TAC AAC AAG TTT AAA GAT ATT GCA AGT ACA CTC Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu 305 310 315 320 | 960 |
| AAC AAG GCT AAG TCC ATT GTG GGT ACC ACT GCT TCA TTA CAG TAT ATG Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met 325 330 335 | 1008 |
| AAA AAT GTT TTT AAA GAG AAA TAT CTC CTA TCT GAA GAT ACA TCT GGA Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly 340 345 350 | 1056 |
| AAA TTT TCG GTA GAT AAA TTA AAA TTT GAT AAG TTA TAC AAA ATG TTA Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu 355 360 365 | 1104 |
| ACA GAG ATT TAC ACA GAG GAT AAT TTT GTT AAG TTT TTT AAA GTA CTT Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu 370 375 380 | 1152 |
| AAC AGA AAA ACA TAT TTG AAT TTT GAT AAA GCC GTA TTT AAG ATA AAT Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn 385 390 395 400 | 1200 |
| ATA GTA CCT AAG GTA AAT TAC ACA ATA TAT GAT GGA TTT AAT TTA AGA Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg 405 410 415 | 1248 |
| AAT ACA AAT TTA GCA GCA AAC TTT AAT GGT CAA AAT ACA GAA ATT AAT Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn 420 425 430 | 1296 |
| AAT ATG AAT TTT ACT AAA CTA AAA AAT TTT ACT GGA TTG TTT GAA TTT Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe 435 440 445 | 1344 |
| TAT AAG TTG CTA TGT GTA AGA GGG ATA ATA ACT TCT AAA ACT AAA TCA Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser 450 455 460 | 1392 |
| TTA GAT AAA GGA TAC AAT AAG GCA TTA AAT GAT TTA TGT ATC AAA GTT Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys Ile Lys Val 465 470 475 480 | 1440 |

| | |
|---|------|
| AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 485 490 495 | 1488 |
| GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala 500 505 510 | 1536 |
| GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr 515 520 525 | 1584 |
| TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser 530 535 540 | 1632 |
| AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe 545 550 555 560 | 1680 |
| CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 565 570 575 | 1728 |
| CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr 580 585 590 | 1776 |
| AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 595 600 605 | 1824 |
| TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 610 615 620 | 1872 |
| ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu 625 630 635 640 | 1920 |
| ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 645 650 655 | 1968 |
| ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 660 665 670 | 2016 |
| GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 675 680 685 | 2064 |
| GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 690 695 700 | 2112 |
| GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 705 710 715 720 | 2160 |
| GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 725 730 735 | 2208 |
| GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 740 745 750 | 2256 |

| | |
|---|------|
| AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 755 760 765 | 2304 |
| ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn 770 775 780 | 2352 |
| ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile 785 790 795 800 | 2400 |
| AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 805 810 815 | 2448 |
| TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 820 825 830 | 2496 |
| GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 835 840 845 | 2544 |
| AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val 850 855 860 | 2592 |
| AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val 865 870 875 880 | 2640 |
| GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys * 885 890 895 | 2685 |

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 895 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

| |
|--|
| Gly Ser Pro Gly Ile His Met Thr Ser Thr Arg Leu Gln Lys Leu Leu 1 5 10 15 |
| Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lys Gln Phe Asn 20 25 30 |
| Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro 35 40 45 |
| Lys Tyr Gly Gln Met Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys 50 55 60 |
| Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly 65 70 75 80 |
| Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr 85 90 95 |
| Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys 100 105 110 |

Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg
 115 120 125
 Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser
 130 135 140
 Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val
 145 150 155 160
 Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile
 165 170 175
 Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly
 180 185 190
 His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr
 195 200 205
 Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu
 210 215 220
 Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro
 225 230 235 240
 Ala Val Thr Leu Ala His Glu Leu Ile His Ala Gly His Arg Leu Tyr
 245 250 255
 Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala
 260 265 270
 Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr
 275 280 285
 Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu
 290 295 300
 Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu
 305 310 315 320
 Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met
 325 330 335
 Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly
 340 345 350
 Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu
 355 360 365
 Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu
 370 375 380
 Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn
 385 390 395 400
 Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg
 405 410 415
 Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn
 420 425 430
 Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe
 435 440 445
 Tyr Lys Leu Leu Cys Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser
 450 455 460

Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys Ile Lys Val
 465 470 475 480
 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
 485 490 495
 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
 500 505 510
 Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
 515 520 525
 Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
 530 535 540
 Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
 545 550 555 560
 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
 565 570 575
 Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
 580 585 590
 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
 595 600 605
 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
 610 615 620
 Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
 625 630 635 640
 Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
 645 650 655
 Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
 660 665 670
 Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
 675 680 685
 Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
 690 695 700
 Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
 705 710 715 720
 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
 725 730 735
 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
 740 745 750
 Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
 755 760 765
 Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
 770 775 780
 Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
 785 790 795 800
 Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
 805 810 815

Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
 820 825 830

Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp
 835 840 845

Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val
 850 855 860

Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
 865 870 875 880

Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys *
 885 890 895

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2622 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..2622

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

| | |
|--|-----|
| GGA TCC ATG GAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA | 48 |
| Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val | |
| 1 5 10 15 | |
| AAC GGT GTT GAC ATT GCC TAC ATC AAA ATT CCA AAG TAC GGC CAG ATG | 96 |
| Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Lys Tyr Gly Gln Met | |
| 20 25 30 | |
| CAG CCG GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG | 144 |
| Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro | |
| 35 40 45 | |
| GAA CGC GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG | 192 |
| Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro | |
| 50 55 60 | |
| CCG GAA GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG | 240 |
| Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu | |
| 65 70 75 80 | |
| AGC ACA GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA | 288 |
| Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu | |
| 85 90 95 | |
| TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA | 336 |
| Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser | |
| 100 105 110 | |
| ATC GTC CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG | 384 |
| Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu | |
| 115 120 125 | |
| TTG AAG GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT | 432 |
| Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly | |
| 130 135 140 | |

| | |
|---|------|
| AGC TAC AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala 145 150 155 160 | 480 |
| GAC ATT ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn 165 170 175 | 528 |
| CTG ACG CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser, Pro 180 185 190 | 576 |
| GAC TTC ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro 195 200 205 | 624 |
| CTG TTG GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala 210 215 220 | 672 |
| CAC GAG CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn 225 230 235 240 | 720 |
| CCG AAC CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser 245 250 255 | 768 |
| GGT TTA GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp 260 265 270 | 816 |
| GCG AAG TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr 275 280 285 | 864 |
| TAC AAC AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser 290 295 300 | 912 |
| ATT GTG GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys 305 310 315 320 | 960 |
| GAG AAA TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp 325 330 335 | 1008 |
| AAA TTA AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr 340 345 350 | 1056 |
| GAG GAT AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr 355 360 365 | 1104 |
| TTG AAT TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val 370 375 380 | 1152 |
| AAT TAC ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala 385 390 395 400 | 1200 |
| GCA AAC TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr 405 410 415 | 1248 |

| | |
|---|------|
| AAA CTA AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys 420 425 430 | 1296 |
| GTA AGA GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr 435 440 445 | 1344 |
| AAT AAG GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG Asn Lys Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu 450 455 460 | 1392 |
| TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly 465 470 475 480 | 1440 |
| GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile 485 490 495 | 1488 |
| AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn 500 505 510 | 1536 |
| GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly 515 520 525 | 1584 |
| CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys 530 535 540 | 1632 |
| TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu 545 550 555 560 | 1680 |
| TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu 565 570 575 | 1728 |
| GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr 580 585 590 | 1776 |
| GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp 595 600 605 | 1824 |
| GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser 610 615 620 | 1872 |
| ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly 625 630 635 640 | 1920 |
| CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly 645 650 655 | 1968 |
| GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu 660 665 670 | 2016 |
| ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala 675 680 685 | 2064 |

- 45 -

| | |
|---|------|
| AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg 690 695 700 | 2112 |
| AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu 705 710 715 720 | 2160 |
| GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu 725 730 735 | 2208 |
| GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln 740 745 750 | 2256 |
| TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile 755 760 765 | 2304 |
| GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile 770 775 780 | 2352 |
| AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn 785 790 795 800 | 2400 |
| TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser 805 810 815 | 2448 |
| CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu 820 825 830 | 2496 |
| ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser 835 840 845 | 2544 |
| ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu 850 855 860 | 2592 |
| TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA Leu Ser Thr Phe Thr Glu Tyr Ile Lys * | 2622 |
| 865 870 | |

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 874 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

| |
|--|
| Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val 1 5 10 15 |
| Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Lys Tyr Gly Gln Met 20 25 30 |
| Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro 35 40 45 |

Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
 50 55 60
 Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
 65 70 75 80
 Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
 85 90 95
 Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
 100 105 110
 Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
 115 120 125
 Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
 130 135 140
 Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
 145 150 155 160
 Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
 165 170 175
 Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
 180 185 190
 Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
 195 200 205
 Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
 210 215 220
 His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
 225 230 235 240
 Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
 245 250 255
 Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
 260 265 270
 Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
 275 280 285
 Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
 290 295 300
 Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
 305 310 315 320
 Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys-Phe Ser Val Asp
 325 330 335
 Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
 340 345 350
 Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
 355 360 365
 Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
 370 375 380
 Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
 385 390 395 400

Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
 405 410 415
 Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
 420 425 430
 Val Arg Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr
 435 440 445
 Asn Lys Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu
 450 455 460
 Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly
 465 470 475 480
 Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile
 485 490 495
 Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn
 500 505 510
 Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly
 515 520 525
 Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys
 530 535 540
 Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu
 545 550 555 560
 Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu
 565 570 575
 Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr
 580 585 590
 Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp
 595 600 605
 Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser
 610 615 620
 Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly
 625 630 635 640
 Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly
 645 650 655
 Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu
 660 665 670
 Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala
 675 680 685
 Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg
 690 695 700
 Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu
 705 710 715 720
 Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu
 725 730 735
 Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln
 740 745 750

- 48 -

Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile
 755 760 765
 Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile
 770 775 780
 Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn
 785 790 795 800
 Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser
 805 810 815
 Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu
 820 825 830
 Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser
 835 840 845
 Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu
 850 855 860
 Leu Ser Thr Phe Thr Glu Tyr Ile Lys *
 865 870

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2613 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2613

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

| | |
|---|-----|
| ATG CCA TTT GTT AAT AAA CAA TTT AAT TAT AAA GAT CCT GTA AAT GGT | 48 |
| Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly | |
| 1 5 10 15 | |
| GTT GAT ATT GCT TAT ATA AAA ATT CCA AAT GCA GGA CAA ATG CAA CCA | 96 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro | |
| 20 25 30 | |
| GTA AAA GCT TTT AAA ATT CAT AAT AAA ATA TGG GTT ATT CCA GAA AGA | 144 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg | |
| 35 40 45 | |
| GAT ACA TTT ACA AAT CCT GAA GAA GGA GAT TTA AAT CCA CCA CCA GAA | 192 |
| Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu | |
| 50 55 60 | |
| GCA AAA CAA GTT CCA GTT TCA TAT TAT GAT TCA ACA TAT TTA AGT ACA | 240 |
| Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr | |
| 65 70 75 80 | |
| GAT AAT GAA AAA GAT AAT TAT TTA AAG GGA GTT ACA AAA TTA TTT GAG | 288 |
| Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu | |
| 85 90 95 | |

| | |
|---|------|
| AGA ATT TAT TCA ACT GAT CTT GGA AGA ATG TTG TTA ACA TCA ATA GTA Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 | 336 |
| AGG GGA ATA CCA TTT TGG GGT GGA AGT ACA ATA GAT ACA GAA TTA AAA Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 | 384 |
| GTT ATT GAT ACT AAT TGT ATT AAT GTG ATA CAA CCA GAT GGT AGT TAT Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 | 432 |
| AGA TCA GAA GAA CTT AAT CTA GTA ATA ATA GGA CCC TCA GCT GAT ATT Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 | 480 |
| ATA CAG TTT GAA TGT AAA AGC TTT GGA CAT GAA GTT TTG AAT CTT ACG Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 | 528 |
| CGA AAT GGT TAT GGC TCT ACT CAA TAC ATT AGA TTT AGC CCA GAT TTT Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190 | 576 |
| ACA TTT GGT TTT GAG GAG TCA CTT GAA GTT GAT ACA AAT CCT CTT TTA Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAA TTT GCT ACA GAT CCA GCA GTA ACA TTA GCA CAT GAA Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTT ATA CAT GCT GGA CAT AGA TTA TAT GGA ATA GCA ATT AAT CCA AAT Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |
| AGG GTT TTT AAA GTA AAT ACT AAT GCC TAT TAT GAA ATG AGT GGG TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTT GAG GAA CTT AGA ACA TTT GGG GGA CAT GAT GCA AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |
| TTT ATA GAT AGT TTA CAG GAA AAC GAA TTT CGT CTA TAT TAT TAT AAT Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATA GCA AGT ACA CTT AAT AAA GCT AAA TCA ATA GTA Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACT ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |

- 50 -

| | |
|---|------|
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 | 1392 |
| AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 | 1440 |
| ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu 485 490 495 | 1488 |
| GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 | 1536 |
| GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu 515 520 525 | 1584 |
| GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 | 1632 |
| TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu 545 550 555 560 | 1680 |
| CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 | 1728 |
| TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 | 1776 |
| AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 | 1824 |
| CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 | 1872 |
| GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala 625 630 635 640 | 1920 |

| | |
|---|------|
| TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 | 1968 |
| ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala 660 665 670 | 2016 |
| ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys 675 680 685 | 2064 |
| GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 | 2112 |
| AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys 705 710 715 720 | 2160 |
| GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 | 2208 |
| GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn 740 745 750 | 2256 |
| CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp 755 760 765 | 2304 |
| TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile 770 775 780 | 2352 |
| AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 | 2400 |
| ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 | 2448 |
| GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly 820 825 830 | 2496 |
| CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 | 2544 |
| ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser 850 855 860 | 2592 |
| ACA TTT ACT GAA TAT ATT AAG Thr Phe Thr Glu Tyr Ile Lys 865 870 | 2613 |

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 871 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```

Met  Pro  Phe  Val  Asn  Lys  Gln  Phe  Asn  Tyr  Lys  Asp  Pro  Val  Asn  Gly
 1          5          10          15
Val  Asp  Ile  Ala  Tyr  Ile  Lys  Ile  Pro  Asn  Ala  Gly  Gln  Met  Gln  Pro
          20          25          30
Val  Lys  Ala  Phe  Lys  Ile  His  Asn  Lys  Ile  Trp  Val  Ile  Pro  Glu  Arg
          35          40          45
Asp  Thr  Phe  Thr  Asn  Pro  Glu  Glu  Gly  Asp  Leu  Asn  Pro  Pro  Pro  Glu
          50          55          60
Ala  Lys  Gln  Val  Pro  Val  Ser  Tyr  Tyr  Asp  Ser  Thr  Tyr  Leu  Ser  Thr
          65          70          75          80
Asp  Asn  Glu  Lys  Asp  Asn  Tyr  Leu  Lys  Gly  Val  Thr  Lys  Leu  Phe  Glu
          85          90          95
Arg  Ile  Tyr  Ser  Thr  Asp  Leu  Gly  Arg  Met  Leu  Leu  Thr  Ser  Ile  Val
          100          105          110
Arg  Gly  Ile  Pro  Phe  Trp  Gly  Gly  Ser  Thr  Ile  Asp  Thr  Glu  Leu  Lys
          115          120          125
Val  Ile  Asp  Thr  Asn  Cys  Ile  Asn  Val  Ile  Gln  Pro  Asp  Gly  Ser  Tyr
          130          135          140
Arg  Ser  Glu  Glu  Leu  Asn  Leu  Val  Ile  Ile  Gly  Pro  Ser  Ala  Asp  Ile
          145          150          155          160
Ile  Gln  Phe  Glu  Cys  Lys  Ser  Phe  Gly  His  Glu  Val  Leu  Asn  Leu  Thr
          165          170          175
Arg  Asn  Gly  Tyr  Gly  Ser  Thr  Gln  Tyr  Ile  Arg  Phe  Ser  Pro  Asp  Phe
          180          185          190
Thr  Phe  Gly  Phe  Glu  Glu  Ser  Leu  Glu  Val  Asp  Thr  Asn  Pro  Leu  Leu
          195          200          205
Gly  Ala  Gly  Lys  Phe  Ala  Thr  Asp  Pro  Ala  Val  Thr  Leu  Ala  His  Glu
          210          215          220
Leu  Ile  His  Ala  Gly  His  Arg  Leu  Tyr  Gly  Ile  Ala  Ile  Asn  Pro  Asn
          225          230          235          240
Arg  Val  Phe  Lys  Val  Asn  Thr  Asn  Ala  Tyr  Tyr  Glu  Met  Ser  Gly  Leu
          245          250          255
Glu  Val  Ser  Phe  Glu  Glu  Leu  Arg  Thr  Phe  Gly  Gly  His  Asp  Ala  Lys
          260          265          270
Phe  Ile  Asp  Ser  Leu  Gln  Glu  Asn  Glu  Phe  Arg  Leu  Tyr  Tyr  Tyr  Asn
          275          280          285
Lys  Phe  Lys  Asp  Ile  Ala  Ser  Thr  Leu  Asn  Lys  Ala  Lys  Ser  Ile  Val
          290          295          300
Gly  Thr  Thr  Ala  Ser  Leu  Gln  Tyr  Met  Lys  Asn  Val  Phe  Lys  Glu  Lys
          305          310          315          320
Tyr  Leu  Leu  Ser  Glu  Asp  Thr  Ser  Gly  Lys  Phe  Ser  Val  Asp  Lys  Leu
          325          330          335

```

- 53 -

Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe
 450 455 460
 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu
 465 470 475 480
 Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu
 485 490 495
 Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro
 500 505 510
 Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu
 515 520 525
 Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu
 530 535 540
 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu
 545 550 555 560
 His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu
 565 570 575
 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys
 580 585 590
 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
 595 600 605
 Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
 610 615 620
 Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala
 625 630 635 640
 Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu
 645 650 655
 Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala
 660 665 670
 Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys
 675 680 685

Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu
690 695 700

Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys
705 710 715 720

Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu
725 730 735

Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn
740 745 750

Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp
755 760 765

Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile
770 775 780

Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met
785 790 795 800

Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys
805 810 815

Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly
820 825 830

Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
835 840 845

Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
850 855 860

Thr Phe Thr Glu Tyr Ile Lys
865 870

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2628 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2628

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

| | |
|---|-----|
| ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT | 48 |
| Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly | |
| 1 5 10 15 | |
| GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG | 96 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro | |
| 20 25 30 | |
| GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC | 144 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg | |
| 35 40 45 | |
| GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA | 192 |
| Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu | |
| 50 55 60 | |

- 55 -

| | |
|---|------|
| GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 | 240 |
| GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 | 288 |
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 | 336 |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 | 384 |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 | 432 |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 | 480 |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 | 528 |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190 | 576 |
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |

| | |
|---|------|
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| AGC GCT GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp 450 455 460 | 1392 |
| GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn 465 470 475 480 | 1440 |
| AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu 485 490 495 | 1488 |
| AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe 500 505 510 | 1536 |
| GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile 515 520 525 | 1584 |
| ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly 530 535 540 | 1632 |
| AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala 545 550 555 560 | 1680 |
| CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val 565 570 575 | 1728 |
| AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser 580 585 590 | 1776 |
| GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu 595 600 605 | 1824 |

| | |
|---|------|
| GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu 610 615 620 | 1872 |
| GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr 625 630 635 640 | 1920 |
| ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe 645 650 655 | 1968 |
| GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile 660 665 670 | 2016 |
| CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 675 680 685 | 2064 |
| ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser 690 695 700 | 2112 |
| AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn 705 710 715 720 | 2160 |
| TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met 725 730 735 | 2208 |
| AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn 740 745 750 | 2256 |
| TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe 755 760 765 | 2304 |
| AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala 770 775 780 | 2352 |
| ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu 785 790 795 800 | 2400 |
| ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 805 810 815 | 2448 |
| GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly 820 825 830 | 2496 |
| ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr 835 840 845 | 2544 |
| CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln 850 855 860 | 2592 |
| AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys * 865 870 875 | 2628 |

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 876 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
 1           5           10           15
Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
          20           25           30
Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
          35           40           45
Asp Thr Phe Thr Asn Pro Glu Gly Asp Leu Asn Pro Pro Pro Glu
          50           55           60
Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
          65           70           75           80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
          85           90           95
Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
          100          105          110
Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
          115          120          125
Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
          130          135          140
Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
          145          150          155          160
Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
          165          170          175
Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
          180          185          190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
          195          200          205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
          210          215          220
Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
          225          230          235          240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
          245          250          255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
          260          265          270
Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
          275          280          285
Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
          290          295          300

```


Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp
 450 455 460
 Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn
 465 470 475 480
 Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu
 485 490 495
 Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe
 500 505 510
 Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile
 515 520 525
 Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly
 530 535 540
 Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala
 545 550 555 560
 Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val
 565 570 575
 Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe-Phe Ser Ser
 580 585 590
 Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu
 595 600 605
 Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu
 610 615 620
 Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr
 625 630 635 640
 Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe
 645 650 655

- 60 -

Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile
660 665 670

Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr
675 680 685

Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser
690 695 700

Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn
705 710 715 720

Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met
725 730 735

Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn
740 745 750

Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe
755 760 765

Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala
770 775 780

Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu
785 790 795 800

Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp
805 810 815

Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly
820 825 830

Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr
835 840 845

Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln
850 855 860

Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys
865 870 875

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2637 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE_TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2637

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

| | |
|---|----|
| ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT | 48 |
| Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly | |
| 1 5 10 15 | |
| GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG | 96 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro | |
| 20 25 30 | |

| | |
|---|-----|
| GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45 | 144 |
| GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA Asp Thr Phe Thr Asn Pro Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 | 192 |
| GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 | 240 |
| GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 | 288 |
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 | 336 |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 | 384 |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 | 432 |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 | 480 |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 | 528 |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190 | 576 |
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |

- 62 -

| | |
|---|------|
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val 450 455 460 | 1392 |
| AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 | 1440 |
| GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala 485 490 495 | 1488 |
| GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr 500 505 510 | 1536 |
| TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser 515 520 525 | 1584 |
| AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe 530 535 540 | 1632 |
| CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 | 1680 |
| CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr 565 570 575 | 1728 |

- 63 -

| | |
|---|------|
| AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 | 1776 |
| TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 | 1824 |
| ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 | 1872 |
| ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 630 635 640 | 1920 |
| ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 645 650 655 | 1968 |
| GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 660 665 670 | 2016 |
| GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 | 2064 |
| GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 690 695 700 | 2112 |
| GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 705 710 715 720 | 2160 |
| GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 725 730 735 | 2208 |
| AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 740 745 750 | 2256 |
| ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 | 2304 |
| ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile 770 775 780 | 2352 |
| AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 785 790 795 800 | 2400 |
| TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 | 2448 |
| GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 825 830 | 2496 |
| AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val 835 840 845 | 2544 |

- 64 -

AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592
 Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
 850 855 860

GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2637
 Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys *
 865 870 875

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 879 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
 1 5 10 15
 Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
 20 25 30
 Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
 35 40 45
 Asp Thr Phe Thr Asn Pro Glu Gly Asp Leu Asn Pro Pro Pro Glu
 50 55 60
 Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
 65 70 75 80
 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
 85 90 95
 Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
 100 105 110
 Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
 115 120 125
 Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
 130 135 140
 Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
 145 150 155 160
 Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
 165 170 175
 Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
 180 185 190
 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
 195 200 205
 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
 210 215 220
 Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
 225 230 235 240
 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
 245 250 255

- 65 -

Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
 260 265 270
 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
 275 280 285
 Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
 290 295 300
 Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val
 450 455 460
 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
 465 470 475 480
 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
 485 490 495
 Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
 500 505 510
 Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
 515 520 525
 Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
 530 535 540
 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
 545 550 555 560
 Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
 565 570 575
 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
 580 585 590
 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
 595 600 605

- 66 -

Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
 610 615 620
 Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
 625 630 635 640
 Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
 645 650 655
 Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
 660 665 670
 Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
 675 680 685
 Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
 690 695 700
 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
 705 710 715 720
 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
 725 730 735
 Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
 740 745 750
 Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
 755 760 765
 Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
 770 775 780
 Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
 785 790 795 800
 Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
 805 810 815
 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp
 820 825 830
 Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val
 835 840 845
 Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
 850 855 860
 Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys *
 865 870 875

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2862 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2862

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

- 67 -

| | |
|---|-----|
| ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 | 48 |
| GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20 25 30 | 96 |
| GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45 | 144 |
| GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 | 192 |
| GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 | 240 |
| GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 | 288 |
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 | 336 |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 | 384 |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 | 432 |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 | 480 |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 | 528 |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190 | 576 |
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |

- 68 -

| | |
|---|------|
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val 450 455 460 | 1392 |
| AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 | 1440 |
| GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala 485 490 495 | 1488 |
| GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr 500 505 510 | 1536 |
| TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser 515 520 525 | 1584 |
| AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe 530 535 540 | 1632 |

- 69 -

| | |
|---|------|
| CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 | 1680 |
| CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr 565 570 575 | 1728 |
| AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 | 1776 |
| TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 | 1824 |
| ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Phe Thr Asp Glu 610 615 620 | 1872 |
| ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 630 635 640 | 1920 |
| ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 645 650 655 | 1968 |
| GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 660 665 670 | 2016 |
| GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 | 2064 |
| GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 690 695 700 | 2112 |
| GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 705 710 715 720 | 2160 |
| GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 725 730 735 | 2208 |
| AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 740 745 750 | 2256 |
| ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 | 2304 |
| ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile 770 775 780 | 2352 |
| AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 785 790 795 800 | 2400 |
| TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 | 2448 |

- 70 -

| | |
|---|------|
| GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 825 830 | 2496 |
| AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val 835 840 845 | 2544 |
| AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val 850 855 860 | 2592 |
| GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG Asp Asn Gln Arg Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Arg 865 870 875 880 | 2640 |
| CCT GGA CCG GAG ACG CTC TGC GGG GCT GAG CTG GTG GAT GCT CTT CAG Pro Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln 885 890 895 | 2688 |
| TTC GTG TGT GGA GAC AGG GGC TTT TAT TTC AAC AAG CCC ACA GGG TAT Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr 900 905 910 | 2736 |
| GGC TCC AGC AGT CGG AGG GCG CCT CAG ACA GGT ATC GTG GAT GAG TGC Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys 915 920 925 | 2784 |
| TGC TTC CGG AGC TGT GAT CTA AGG AGG CTG GAG ATG TAT TGC GCA CCC Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro 930 935 940 | 2832 |
| CTC AAG CCT GCC AAG TCA GCT GAA GCT TAG Leu Lys Pro Ala Lys Ser Ala Glu Ala 945 950 | 2862 |

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 954 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

| |
|--|
| Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20 25 30 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45 |
| Asp Thr Phe Thr Asn Pro Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 |
| Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 |
| Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 |
| Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 |

- 71 -

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
 115 120 125
 Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
 130 135 140
 Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
 145 150 155 160
 Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
 165 170 175
 Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
 180 185 190
 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
 195 200 205
 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
 210 215 220
 Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
 225 230 235 240
 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
 245 250 255
 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
 260 265 270
 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
 275 280 285
 Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
 290 295 300
 Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val
 450 455 460

- 72 -

Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
 465 470 475 480
 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
 485 490 495
 Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
 500 505 510
 Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
 515 520 525
 Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
 530 535 540
 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
 545 550 555 560
 Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
 565 570 575
 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
 580 585 590
 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
 595 600 605
 Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
 610 615 620
 Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
 625 630 635 640
 Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
 645 650 655
 Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
 660 665 670
 Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
 675 680 685
 Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
 690 695 700
 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
 705 710 715 720
 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
 725 730 735
 Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
 740 745 750
 Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
 755 760 765
 Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
 770 775 780
 Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
 785 790 795 800
 Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
 805 810 815

[illegible]

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2724 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..2724

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ATG | CAG | TTC | GTG | AAC | AAG | CAG | TTC | AAC | TAT | AAG | GAC | CCT | GTA | AAC | GGT | 48 |
| Met | Gln | Phe | Val | Asn | Lys | Gln | Phe | Asn | Tyr | Lys | Asp | Pro | Val | Asn | Gly | |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | | |
| GTG | GAC | ATT | GCC | TAC | ATC | AAA | ATT | CCA | AAC | GCC | GGC | CAG | ATG | CAG | CCG | 96 |
| Val | Asp | Ile | Ala | Tyr | Ile | Lys | Ile | Pro | Asn | Ala | Gly | Gln | Met | Gln | Pro | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| GTG | AAG | GCT | TTC | AAG | ATT | CAT | AAC | AAA | ATC | TGG | GTT | ATT | CCG | GAA | CGC | 144 |
| Val | Lys | Ala | Phe | Lys | Ile | His | Asn | Lys | Ile | Trp | Val | Ile | Pro | Glu | Arg | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| GAT | ACA | TTT | ACG | AAC | CCG | GAA | GAA | GGA | GAC | TTG | AAC | CCG | CCG | CCG | GAA | 192 |
| Asp | Thr | Phe | Thr | Asn | Pro | Glu | Glu | Gly | Asp | Leu | Asn | Pro | Pro | Pro | Glu | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| GCA | AAG | CAG | GTG | CCA | GTT | TCA | TAC | TAC | GAT | TCA | ACC | TAT | CTG | AGC | ACA | 240 |
| Ala | Lys | Gln | Val | Pro | Val | Ser | Tyr | Tyr | Asp | Ser | Thr | Tyr | Leu | Ser | Thr | |
| 65 | | | | 70 | | | | | 75 | | | | | | 80 | |
| GAC | AAC | GAG | AAG | GAT | AAC | TAC | CTG | AAG | GGA | GTG | ACC | AAA | TTA | TTC | GAG | 288 |
| Asp | Asn | Glu | Lys | Asp | Asn | Tyr | Leu | Lys | Gly | Val | Thr | Lys | Leu | Phe | Glu | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |

- 74 -

| | |
|---|------|
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 | 336 |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys 115 120 125 | 384 |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140 | 432 |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile 145 150 155 160 | 480 |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 | 528 |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190 | 576 |
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |

- 75 -

| | |
|---|------|
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT Ile Glu Gly Arg Cys Asp Glu Ala Leu Asn Asp Leu Cys Ile Lys Val 450 455 460 | 1392 |
| AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 | 1440 |
| GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala 485 490 495 | 1488 |
| GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr 500 505 510 | 1536 |
| TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser 515 520 525 | 1584 |
| AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe 530 535 540 | 1632 |
| CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 | 1680 |
| CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr 565 570 575 | 1728 |
| AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590 | 1776 |
| TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 | 1824 |
| ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 | 1872 |
| ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 630 635 640 | 1920 |

- 76 -

| | |
|---|------|
| ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 645 650 655 | 1968 |
| GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 660 665 670 | 2016 |
| GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 | 2064 |
| GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 690 695 700 | 2112 |
| GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 705 710 715 720 | 2160 |
| GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 725 730 735 | 2208 |
| AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 740 745 750 | 2256 |
| ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765 | 2304 |
| ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile 770 775 780 | 2352 |
| AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 785 790 795 800 | 2400 |
| TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 | 2448 |
| GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 825 830 | 2496 |
| AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val 835 840 845 | 2544 |
| AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val 850 855 860 | 2592 |
| GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Arg 865 870 875 880 | 2640 |
| CCT CAA TCT AAA GTT AAA AGA CAA ATA TTT TCA GGC TAT CAA TCT GAT Pro Gln Ser Lys Val Lys Arg Gln Ile Phe Ser Gly Tyr Gln Ser Asp 885 890 895 | 2688 |
| ATT GAT ACA CAT AAT AGA ATT AAG GAT GAA TTA TGA Ile Asp Thr His Asn Arg Ile Lys Asp Glu Leu * 900 905 | 2724 |

- 77 -

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 908 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

```

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
 1              5              10              15

Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
      20              25              30

Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
      35              40              45

Asp Thr Phe Thr Asn Pro Glu Gly Asp Leu Asn Pro Pro Pro Glu
      50              55              60

Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
      65              70              75              80

Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
      85              90              95

Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
      100             105             110

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
      115             120             125

Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
      130             135             140

Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
      145             150             155             160

Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
      165             170             175

Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
      180             185             190

Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
      195             200             205

Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
      210             215             220

Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
      225             230             235             240

Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
      245             250             255

Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
      260             265             270

Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
      275             280             285

Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
      290             295             300

```

- 78 -

Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val
 450 455 460
 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
 465 470 475 480
 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
 485 490 495
 Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
 500 505 510
 Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
 515 520 525
 Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
 530 535 540
 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
 545 550 555 560
 Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
 565 570 575
 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
 580 585 590
 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
 595 600 605
 Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
 610 615 620
 Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
 625 630 635 640
 Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
 645 650 655

- 79 -

Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
 660 665 670
 Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
 675 680 685
 Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
 690 695 700
 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
 705 710 715 720
 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
 725 730 735
 Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
 740 745 750
 Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
 755 760 765
 Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
 770 775 780
 Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
 785 790 795 800
 Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
 805 810 815
 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp
 820 825 830
 Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val
 835 840 845
 Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
 850 855 860
 Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Arg
 865 870 875 880
 Pro Gln Ser Lys Val Lys Arg Gln Ile Phe Ser Gly Tyr Gln Ser Asp
 885 890 895
 Ile Asp Thr His Asn Arg Ile Lys Asp Glu Leu *
 900 905

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 3042 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..3042

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT
 Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
 1 5 10 15

- 80 -

| | |
|---|-----|
| GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG | 96 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro | |
| 20 25 30 | |
| GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC | 144 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg | |
| 35 40 45 | |
| GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA | 192 |
| Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu | |
| 50 55 60 | |
| GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA | 240 |
| Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr | |
| 65 70 75 80 | |
| GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG | 288 |
| Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu | |
| 85 90 95 | |
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC | 336 |
| Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val | |
| 100 105 110 | |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG | 384 |
| Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys | |
| 115 120 125 | |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC | 432 |
| Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr | |
| 130 135 140 | |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT | 480 |
| Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile | |
| 145 150 155 160 | |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG | 528 |
| Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr | |
| 165 170 175 | |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC | 576 |
| Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe | |
| 180 185 190 | |
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG | 624 |
| Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu | |
| 195 200 205 | |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG | 672 |
| Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu | |
| 210 215 220 | |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC | 720 |
| Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn | |
| 225 230 235 240 | |
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA | 768 |
| Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu | |
| 245 250 255 | |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG | 816 |
| Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys | |
| 260 265 270 | |
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC | 864 |
| Ph Ile Asp Ser Leu Gln Glu Asn Glu Ph Arg Leu Tyr Tyr Tyr Asn | |
| 275 280 285 | |

- 81 -

| | |
|---|------|
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val 450 455 460 | 1392 |
| AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480 | 1440 |
| GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala 485 490 495 | 1488 |
| GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr 500 505 510 | 1536 |
| TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser 515 520 525 | 1584 |
| AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe 530 535 540 | 1632 |
| CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 | 1680 |

- 82 -

| | |
|---|------|
| CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr 565 570 575 | 1728 |
| AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Thr Phe 580 585 590 | 1776 |
| TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 | 1824 |
| ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620 | 1872 |
| ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile 625 630 635 640 | 1920 |
| ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys 645 650 655 | 1968 |
| GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu 660 665 670 | 2016 |
| GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu 675 680 685 | 2064 |
| GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn 690 695 700 | 2112 |
| GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile 705 710 715 720 | 2160 |
| GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg 725 730 735 | 2208 |
| AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala 740 745 750 | 2256 |
| ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Lys Lys Asn Asn 755 760 765 | 2304 |
| ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile 770 775 780 | 2352 |
| AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val 785 790 795 800 | 2400 |
| TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 | 2448 |
| GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp 820 825 830 | 2496 |

- 83 -

| | |
|---|------|
| AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val 835 840 845 | 2544 |
| AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val 850 855 860 | 2592 |
| GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCA GGC Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Gly 865 870 875 880 | 2640 |
| CTG AAT TCC CCG GGT GCA GCT CAT TAT GCG CAA CAC GAT GAA GCC GTA Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gln His Asp Glu Ala Val 885 890 895 | 2688 |
| GAC AAC AAA TTC AAC AAA GAA CAA CAA AAC GCG TTC TAT GAG ATC TTA Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu 900 905 910 | 2736 |
| CAT TTA CCT AAC TTA AAC GAA GAA CAA CGA AAC GCC TTC ATC CAA AGT His Leu Pro Asn Leu Asn Glu Gln Gln Arg Asn Ala Phe Ile Gln Ser 915 920 925 | 2784 |
| TTA AAA GAT GAC CCA AGC CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA Leu Lys Asp Asp Pro Ser Ser Ala Asn Leu Leu Ala Glu Ala Lys 930 935 940 | 2832 |
| AAG CTA AAT GAT GCT CAG GCG CCG AAA GTA GAC AAC AAA TTC AAC AAA Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn Lys 945 950 955 960 | 2880 |
| GAA CAA CAA AAC GCG TTC TAT GAG ATC TTA CAT TTA CCT AAC TTA AAC Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn 965 970 975 | 2928 |
| GAA GAA CAA CGA AAC GCC TTC ATC CAA AGT TTA AAA GAT GAC CCA AGC Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser 980 985 990 | 2976 |
| CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA AAG CTA AAT GAT GCT CAG Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln 995 1000 1005 | 3024 |
| GCG CCG AAA GTA GAC TAG Ala Pro Lys Val Asp * 1010 | 3042 |

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1014 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
1 5 10 15

Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
20 25 30

Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
35 40 45

- 84 -

Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu
 50 55 60
 Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
 65 70 75 80
 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
 85 90 95
 Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
 100 105 110
 Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
 115 120 125
 Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
 130 135 140
 Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
 145 150 155 160
 Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
 165 170 175
 Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
 180 185 190
 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
 195 200 205
 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
 210 215 220
~~Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn~~
~~225 230 235 240~~
 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
 245 250 255
 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
 260 265 270
 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
 275 280 285
 Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
 290 295 300
 Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400

- 85 -

Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ile Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys Ile Lys Val
 450 455 460
 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
 465 470 475 480
 Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
 485 490 495
 Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
 500 505 510
 Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
 515 520 525
 Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
 530 535 540
 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
 545 550 555 560
 Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
 565 570 575
 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
 580 585 590
 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
 595 600 605
 Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
 610 615 620
 Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
 625 630 635 640
 Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
 645 650 655
 Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
 660 665 670
 Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
 675 680 685
 Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
 690 695 700
 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
 705 710 715 720
 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
 725 730 735
 Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
 740 745 750

- 86 -

Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
 755 760 765
 Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
 770 775 780
 Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
 785 790 795 800
 Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
 805 810 815
 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp
 820 825 830
 Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val
 835 840 845
 Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
 850 855 860
 Asp Asn Gln Arg Leu Leu Ser Thr Phe Thr Glu Tyr Ile Lys Ser Gly
 865 870 875 880
 Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gln His Asp Glu Ala Val
 885 890 895
 Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu
 900 905 910
 His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser
 915 920 925
 Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys
 930 935 940
 Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn Lys
 945 950 955 960
 Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn
 965 970 975
 Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser
 980 985 990
 Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln
 995 1000 1005
 Ala Pro Lys Val Asp *
 1010

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3509 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..3509

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

- 87 -

| | |
|---|-----|
| ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn 1 5 10 15 | 48 |
| AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30 | 96 |
| TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu 35 40 45 | 144 |
| AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60 | 192 |
| ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80 | 240 |
| ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe 85 90 95 | 288 |
| AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile 100 105 110 | 336 |
| ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125 | 384 |
| TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn 130 135 140 | 432 |
| CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile 145 150 155 160 | 480 |
| TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly 165 170 175 | 528 |
| ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln 180 185 190 | 576 |
| ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu 195 200 205 | 624 |
| AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 | 672 |
| GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr 225 230 235 240 | 720 |
| GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe 245 250 255 | 768 |
| TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe 260 265 270 | 816 |

- 88 -

| | |
|--|------|
| GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile | 864 |
| 275 280 285 | |
| TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn | 912 |
| 290 295 300 | |
| AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr | 960 |
| 305 310 315 320 | |
| AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly | 1008 |
| 325 330 335 | |
| AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu | 1056 |
| 340 345 350 | |
| ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys | 1104 |
| 355 360 365 | |
| ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys | 1152 |
| 370 375 380 | |
| AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile | 1200 |
| 385 390 395 400 | |
| TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile | 1248 |
| 405 410 415 | |
| AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr | 1296 |
| 420 425 430 | |
| AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp | 1344 |
| 435 440 445 | |
| GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA Val Asp Asn Glu Asp Leu Phe Ile Ala Asp Lys Asn Ser Phe Ser | 1392 |
| 450 455 460 | |
| GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn | 1440 |
| 465 470 475 480 | |
| TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp | 1488 |
| 485 490 495 | |
| TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr | 1536 |
| 500 505 510 | |
| GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys | 1584 |
| 515 520 525 | |
| AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln | 1632 |
| 530 535 540 | |

- 89 -

| | |
|---|------|
| ACA TTT CCT CTA GAT ATA AGA GAT ATA AGT TTA ACA TCT TCA TTT GAT Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp 545 550 555 560 | 1680 |
| GAT GCA TTA TTA TTT TCT AAC AAA GTT TAT TCA TTT TTT TCT ATG GAT Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575 | 1728 |
| TAT ATT AAA ACT GCT AAT AAA GTG GTA GAA GCA GGA TTA TTT GCA GGT Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590 | 1776 |
| TGG GTG AAA CAG ATA GTA AAT GAT TTT GTA ATC GAA GCT AAT AAA AGC Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser 595 600 605 | 1824 |
| AAT ACT ATG GAT AAA ATT GCA GAT ATA TCT CTA ATT GTT CCT TAT ATA Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile 610 615 620 | 1872 |
| GGA TTA GCT TTA AAT GTA GGA AAT GAA ACA GCT AAA GGA AAT TTT GAA Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640 | 1920 |
| AAT GCT TTT GAG ATT GCA GGA GCC AGT ATT CTA CTA GAA TTT ATA CCA Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro 645 650 655 | 1968 |
| GAA CTT TTA ATA CCT GTA GTT GGA GCC TTT TTA TTA GAA TCA TAT ATT Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile 660 665 670 | 2016 |
| GAC AAT AAA AAT AAA ATT ATT AAA ACA ATA GAT AAT GCT TTA ACT AAA Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys 675 680 685 | 2064 |
| AGA AAT GAA AAA TGG AGT GAT ATG TAC GGA TTA ATA GTA GCG CAA TGG Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp 690 695 700 | 2112 |
| CTC TCA ACA GTT AAT ACT CAA TTT TAT ACA ATA AAA GAG GGA ATG TAT Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr 705 710 715 720 | 2160 |
| AAG GCT TTA AAT TAT CAA GCA CAA GCA TTG GAA GAA ATA ATA AAA TAC Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr 725 730 735 | 2208 |
| AGA TAT AAT ATA TAT TCT GAA AAA GAA AAG TCA AAT ATT AAC ATC GAT Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp 740 745 750 | 2256 |
| TTT AAT GAT ATA AAT TCT AAA CTT AAT GAG GGT ATT AAC CAA GCT ATA Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile 755 760 765 | 2304 |
| GAT AAT ATA AAT AAT TTT ATA AAT GGA TGT TCT GTA TCA TAT TTA ATG Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780 | 2352 |
| AAA AAA ATG ATT CCA TTA GCT GTA GAA AAA TTA CTA GAC TTT GAT AAT Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800 | 2400 |
| ACT CTC AAA AAA AAT TTG TTA AAT TAT ATA GAT GAA AAT AAA TTA TAT Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr 805 810 815 | 2448 |

- 90 -

| | |
|--|------|
| TTG ATT GGA AGT GCA GAA TAT GAA AAA TCA AAA GTA AAT AAA TAC TTG Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830 | 2496 |
| AAA ACC ATT ATG CCG TTT GAT CTT TCA ATA TAT ACC AAT GAT ACA ATA Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile 835 840 845 | 2544 |
| CTA ATA GAA ATG TTT AAT AAA TAT AAT AGC GAA ATT TTA AAT AAT ATT Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser Glu Ile Leu Asn Asn Ile 850 855 860 | 2592 |
| ATC TTA AAT TTA AGA TAT AAG GAT AAT AAT TTA ATA GAT TTA TCA GGA Ile Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu Ile Asp Leu Ser Gly 865 870 875 880 | 2640 |
| TAT GGG GCA AAG GTA GAG GTA TAT GAT GGA GTC GAG CTT AAT GAT AAA Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 895 | 2688 |
| AAT CAA TTT AAA TTA ACT AGT TCA GCA AAT AGT AAG ATT AGA GTG ACT Asn Gln Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys Ile Arg Val Thr 900 905 910 | 2736 |
| CAA AAT CAG AAT ATC ATA TTT AAT AGT GTG TTC CTT GAT TTT AGC GTT Gln Asn Gln Asn Ile Ile Phe Asn Ser Val Phe Leu Asp Phe Ser Val 915 920 925 | 2784 |
| AGC TTT TGG ATA AGA ATA CCT AAA TAT AAG AAT GAT GGT ATA CAA AAT Ser Phe Trp Ile Arg Ile Pro Lys Tyr Lys Asn Asp Gly Ile Gln Asn 930 935 940 | 2832 |
| TAT ATT CAT AAT GAA TAT ACA ATA ATT AAT TGT ATG AAA AAT AAT TCG Tyr Ile His Asn Glu Tyr Thr Ile Ile Asn Cys Met Lys Asn Asn Ser 945 950 955 960 | 2880 |
| GGC TGG AAA ATA TCT ATT AGG GGT AAT AGG ATA ATA TGG ACT TTA ATT Gly Trp Lys Ile Ser Ile Arg Gly Asn Arg Ile Ile Trp Thr Leu Ile 965 970 975 | 2928 |
| GAT ATA AAT GGA AAA ACC AAA TCG GTA TTT TTT GAA TAT AAC ATA AGA Asp Ile Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn Ile Arg 980 985 990 | 2976 |
| GAA GAT ATA TCA GAG TAT ATA AAT AGA TGG TTT TTT GTA ACT ATT ACT Glu Asp Ile Ser Glu Tyr Ile Asn Arg Trp Phe Phe Val Thr Ile Thr 995 1000 1005 | 3024 |
| AAT AAT TTG AAT AAC GCT AAA ATT TAT ATT AAT GGT AAG CTA GAA TCA Asn Asn Leu Asn Asn Ala Lys Ile Tyr Ile Asn Gly Lys Leu Glu Ser 1010 1015 1020 | 3072 |
| AAT ACA GAT ATT AAA GAT ATA AGA GAA GTT ATT GCT AAT GGT GAA ATA Asn Thr Asp Ile Lys Asp Ile Arg Glu Val Ile Ala Asn Gly Glu Ile 1025 1030 1035 1040 | 3120 |
| ATA TTT AAA TTA GAT GGT GAT ATA GAT AGA ACA CAA TTT ATT TGG ATG Ile Phe Lys Leu Asp Gly Asp Ile Asp Arg Thr Gln Phe Ile Trp Met 1045 1050 1055 | 3168 |
| AAA TAT TTC AGT ATT TTT AAT ACG GAA TTA AGT CAA TCA AAT ATT GAA Lys Tyr Phe Ser Ile Phe Asn Thr Glu Leu Ser Gln Ser Asn Ile Glu 1060 1065 1070 | 3216 |
| GAA AGA TAT AAA ATT CAA TCA TAT AGC GAA TAT TTA AAA GAT TTT TGG Glu Arg Tyr Lys Ile Gln Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp 1075 1080 1085 | 3264 |

- 91 -

GGA AAT CCT TTA ATG TAC AAT AAA GAA TAT TAT ATG TTT AAT GCG GGG 3312
 Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly
 1090 1095 1100

AAT AAA AAT TCA TAT ATT AAA CTA AAG AAA GAT TCA CCT GTA GGT GAA 3360
 Asn Lys Asn Ser Tyr Ile Lys Leu Lys Lys Asp Ser Pro Val Gly Glu
 1105 1110 1115 1120

ATT TTA ACA CGT AGC AAA TAT AAT CAA AAT TCT AAA TAT ATA AAT TAT 3408
 Ile Leu Thr Arg Ser Lys Tyr Asn Gln Asn Ser Lys Tyr Ile Asn Tyr
 1125 1130 1135

AGA GAT TTA TAT ATT GGA GAA AAA TTT ATT ATA AGA AGA AAG TCA AAT 3456
 Arg Asp Leu Tyr Ile Gly Glu Lys Phe Ile Ile Arg Arg Lys Ser Asn
 1140 1145 1150

TCT CAA TCT ATA AAT GAT GAT ATA GTT AGA AAA GAA GAT TAT ATA TAT 3504
 Ser Gln Ser Ile Asn Asp Asp Ile Val Arg Lys Glu Asp Tyr Ile Tyr
 1155 1160 1165

CTA GA 3509
 Leu

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1169 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn
 1 5 10 15

Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg
 20 25 30

Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu
 35 40 45

Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly
 50 55 60

Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn
 65 70 75 80

Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe
 85 90 95

Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile
 100 105 110

Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu
 115 120 125

Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn
 130 135 140

Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile
 145 150 155 160

Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly
 165 170 175

- 92 -

Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln
 180 185 190
 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu
 195 200 205
 Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro
 210 215 220
 Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
 225 230 235 240
 Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe
 245 250 255
 Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe
 260 265 270
 Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile
 275 280 285
 Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn
 290 295 300
 Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr
 305 310 315 320
 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
 325 330 335
 Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu
 340 345 350
 Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys
 355 360 365
 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys
 370 375 380
 Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile
 385 390 395 400
 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile
 405 410 415
 Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr
 420 425 430
 Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp
 435 440 445
 Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser
 450 455 460
 Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn
 465 470 475 480
 Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp
 485 490 495
 Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr
 500 505 510
 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys
 515 520 525

- 93 -

Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln
 530 535 540
 Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp
 545 550 555 560
 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp
 565 570 575
 Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly
 580 585 590
 Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser
 595 600 605
 Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile
 610 615 620
 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu
 625 630 635 640
 Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro
 645 650 655
 Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile
 660 665 670
 Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys
 675 680 685
 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp
 690 695 700
 Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr
 705 710 715 720
 Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr
 725 730 735
 Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp
 740 745 750
 Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile
 755 760 765
 Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met
 770 775 780
 Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn
 785 790 795 800
 Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr
 805 810 815
 Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu
 820 825 830
 Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile
 835 840 845
 Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser Glu Ile Leu Asn Asn Ile
 850 855 860
 Ile Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu Ile Asp Leu Ser Gly
 865 870 875 880

- 94 -

Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys
 885 890 895
 Asn Gln Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys Ile Arg Val Thr
 900 905 910
 Gln Asn Gln Asn Ile Ile Phe Asn Ser Val Phe Leu Asp Phe Ser Val
 915 920 925
 Ser Phe Trp Ile Arg Ile Pro Lys Tyr Lys Asn Asp Gly Ile Gln Asn
 930 935 940
 Tyr Ile His Asn Glu Tyr Thr Ile Ile Asn Cys Met Lys Asn Asn Ser
 945 950 955 960
 Gly Trp Lys Ile Ser Ile Arg Gly Asn Arg Ile Ile Trp Thr Leu Ile
 965 970 975
 Asp Ile Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn Ile Arg
 980 985 990
 Glu Asp Ile Ser Glu Tyr Ile Asn Arg Trp Phe Phe Val Thr Ile Thr
 995 1000 1005
 Asn Asn Leu Asn Asn Ala Lys Ile Tyr Ile Asn Gly Lys Leu Glu Ser
 1010 1015 1020
 Asn Thr Asp Ile Lys Asp Ile Arg Glu Val Ile Ala Asn Gly Glu Ile
 1025 1030 1035 1040
 Ile Phe Lys Leu Asp Gly Asp Ile Asp Arg Thr Gln Phe Ile Trp Met
 1045 1050 1055
 Lys Tyr Phe Ser Ile Phe Asn Thr Glu Leu Ser Gln Ser Asn Ile Glu
 1060 1065 1070
 Glu Arg Tyr Lys Ile Gln Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp
 1075 1080 1085
 Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly
 1090 1095 1100
 Asn Lys Asn Ser Tyr Ile Lys Leu Lys Lys Asp Ser Pro Val Gly Glu
 1105 1110 1115 1120
 Ile Leu Thr Arg Ser Lys Tyr Asn Gln Asn Ser Lys Tyr Ile Asn Tyr
 1125 1130 1135
 Arg Asp Leu Tyr Ile Gly Glu Lys Phe Ile Ile Arg Arg Lys Ser Asn
 1140 1145 1150
 Ser Gln Ser Ile Asn Asp Asp Ile Val Arg Lys Glu Asp Tyr Ile Tyr
 1155 1160 1165
 Leu

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2574 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 95 -

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..2574

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

| | |
|---|-----|
| ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT | 48 |
| Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn | |
| 1 5 10 15 | |
| AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA | 96 |
| Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg | |
| 20 25 30 | |
| TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA | 144 |
| Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu | |
| 35 40 45 | |
| AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT | 192 |
| Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly | |
| 50 55 60 | |
| ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT | 240 |
| Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn | |
| 65 70 75 80 | |
| ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT | 288 |
| Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe | |
| 85 90 95 | |
| AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT | 336 |
| Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile | |
| 100 105 110 | |
| ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG | 384 |
| Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu | |
| 115 120 125 | |
| TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT | 432 |
| Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn | |
| 130 135 140 | |
| CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA | 480 |
| Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile | |
| 145 150 155 160 | |
| TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT | 528 |
| Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly | |
| 165 170 175 | |
| ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA | 576 |
| Ile Gln Asn His Phe Ala Ser Arg Gly Phe Gly Gly Ile Met Gln | |
| 180 185 190 | |
| ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA | 624 |
| Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu | |
| 195 200 205 | |
| AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA | 672 |
| Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro | |
| 210 215 220 | |
| GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT | 720 |
| Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr | |
| 225 230 235 240 | |

- 96 -

| | |
|---|------|
| GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe 245 250 255 | 768 |
| TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe 260 265 270 | 816 |
| GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile 275 280 285 | 864 |
| TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn 290 295 300 | 912 |
| AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr 305 310 315 320 | 960 |
| AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 | 1008 |
| AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 | 1056 |
| ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys 355 360 365 | 1104 |
| ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys 370 375 380 | 1152 |
| AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile 385 390 395 400 | 1200 |
| TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile 405 410 415 | 1248 |
| AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr 420 425 430 | 1296 |
| AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp 435 440 445 | 1344 |
| GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser 450 455 460 | 1392 |
| GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn 465 470 475 480 | 1440 |
| TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp 485 490 495 | 1488 |
| TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 | 1536 |

- 97 -

| | |
|---|------|
| GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA | 1584 |
| Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys | |
| 515 520 525 | |
| AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG | 1632 |
| Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln | |
| 530 535 540 | |
| ACA TTT CCT CTA GAT ATA AGA GAT ATA AGT TTA ACA TCT TCA TTT GAT | 1680 |
| Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp | |
| 545 550 555 560 | |
| GAT GCA TTA TTA TTT TCT AAC AAA GTT TAT TCA TTT TTT TCT ATG GAT | 1728 |
| Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp | |
| 565 570 575 | |
| TAT ATT AAA ACT GCT AAT AAA GTG GTA GAA GCA GGA TTA TTT GCA GGT | 1776 |
| Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly | |
| 580 585 590 | |
| TGG GTG AAA CAG ATA GTA AAT GAT TTT GTA ATC GAA GCT AAT AAA AGC | 1824 |
| Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser | |
| 595 600 605 | |
| AAT ACT ATG GAT AAA ATT GCA GAT ATA TCT CTA ATT GTT CCT TAT ATA | 1872 |
| Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile | |
| 610 615 620 | |
| GGA TTA GCT TTA AAT GTA GGA AAT GAA ACA GCT AAA GGA AAT TTT GAA | 1920 |
| Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu | |
| 625 630 635 640 | |
| AAT GCT TTT GAG ATT GCA GGA GCC AGT ATT CTA CTA GAA TTT ATA CCA | 1968 |
| Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro | |
| 645 650 655 | |
| GAA CTT TTA ATA CCT GTA GTT GGA GCC TTT TTA TTA GAA TCA TAT ATT | 2016 |
| Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile | |
| 660 665 670 | |
| GAC AAT AAA AAT AAA ATT ATT AAA ACA ATA GAT AAT GCT TTA ACT AAA | 2064 |
| Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys | |
| 675 680 685 | |
| AGA AAT GAA AAA TGG AGT GAT ATG TAC GGA TTA ATA GTA GCG CAA TGG | 2112 |
| Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp | |
| 690 695 700 | |
| CTC TCA ACA GTT AAT ACT CAA TTT TAT ACA ATA AAA GAG GGA ATG TAT | 2160 |
| Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr | |
| 705 710 715 720 | |
| AAG GCT TTA AAT TAT CAA GCA CAA GCA TTG GAA GAA ATA ATA AAA TAC | 2208 |
| Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr | |
| 725 730 735 | |
| AGA TAT AAT ATA TAT TCT GAA AAA GAA AAG TCA AAT ATT AAC ATC GAT | 2256 |
| Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp | |
| 740 745 750 | |
| TTT AAT GAT ATA AAT TCT AAA CTT AAT GAG GGT ATT AAC CAA GCT ATA | 2304 |
| Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile | |
| 755 760 765 | |
| GAT AAT ATA AAT AAT TTT ATA AAT GGA TGT TCT GTA TCA TAT TTA ATG | 2352 |
| Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met | |
| 770 775 780 | |

- 98 -

| | |
|---|------|
| AAA AAA ATG ATT CCA TTA GCT GTA GAA AAA TTA CTA GAC TTT GAT AAT Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800 | 2400 |
| ACT CTC AAA AAA AAT TTG TTA AAT TAT ATA GAT GAA AAT AAA TTA TAT Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr 805 810 815 | 2448 |
| TTG ATT GGA AGT GCA GAA TAT GAA AAA TCA AAA GTA AAT AAA TAC TTG Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830 | 2496 |
| AAA ACC ATT ATG CCG TTT GAT CTT TCA ATA TAT ACC AAT GAT ACA ATA Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile 835 840 845 | 2544 |
| CTA ATA GAA ATG TTT AAT AAA TAT AAT AGC Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser 850 855 | 2574 |

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 858 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Pro | Val | Thr | Ile | Asn | Asn | Phe | Asn | Tyr | Asn | Asp | Pro | Ile | Asp | Asn | 1 | 5 | 10 | 15 |
| Asn | Asn | Ile | Ile | Met | Met | Glu | Pro | Pro | Phe | Ala | Arg | Gly | Thr | Gly | Arg | 20 | 25 | 30 | |
| Tyr | Tyr | Lys | Ala | Phe | Lys | Ile | Thr | Asp | Arg | Ile | Trp | Ile | Ile | Pro | Glu | 35 | 40 | 45 | |
| Arg | Tyr | Thr | Phe | Gly | Tyr | Lys | Pro | Glu | Asp | Phe | Asn | Lys | Ser | Ser | Gly | 50 | 55 | 60 | |
| Ile | Phe | Asn | Arg | Asp | Val | Cys | Glu | Tyr | Tyr | Asp | Pro | Asp | Tyr | Leu | Asn | 65 | 70 | 75 | 80 |
| Thr | Asn | Asp | Lys | Lys | Asn | Ile | Phe | Leu | Gln | Thr | Met | Ile | Lys | Leu | Phe | 85 | 90 | 95 | |
| Asn | Arg | Ile | Lys | Ser | Lys | Pro | Leu | Gly | Glu | Lys | Leu | Leu | Glu | Met | Ile | 100 | 105 | 110 | |
| Ile | Asn | Gly | Ile | Pro | Tyr | Leu | Gly | Asp | Arg | Arg | Val | Pro | Leu | Glu | Glu | 115 | 120 | 125 | |
| Phe | Asn | Thr | Asn | Ile | Ala | Ser | Val | Thr | Val | Asn | Lys | Leu | Ile | Ser | Asn | 130 | 135 | 140 | |
| Pro | Gly | Glu | Val | Glu | Arg | Lys | Lys | Gly | Ile | Phe | Ala | Asn | Leu | Ile | Ile | 145 | 150 | 155 | 160 |
| Phe | Gly | Pro | Gly | Pro | Val | Leu | Asn | Glu | Asn | Glu | Thr | Ile | Asp | Ile | Gly | 165 | 170 | 175 | |
| Ile | Gln | Asn | His | Phe | Ala | Ser | Arg | Glu | Gly | Phe | Gly | Gly | Ile | Met | Gln | 180 | 185 | 190 | |

- 99 -

Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu
 195 200 205
 Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro
 210 215 220
 Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
 225 230 235 240
 Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe
 245 250 255
 Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe
 260 265 270
 Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile
 275 280 285
 Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn
 290 295 300
 Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr
 305 310 315 320
 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
 325 330 335
 Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu
 340 345 350
 Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys
 355 360 365
 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys
 370 375 380
 Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile
 385 390 395 400
 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile
 405 410 415
 Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr
 420 425 430
 Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp
 435 440 445
 Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser
 450 455 460
 Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn
 465 470 475 480
 Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp
 485 490 495
 Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr
 500 505 510
 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys
 515 520 525
 Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln
 530 535 540

- 100 -

Thr Phe Pro Leu Asp Ile Arg Asp Ile Ser L u Thr Ser Ser Phe Asp
 545 550 555 560
 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp
 565 570 575
 Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly
 580 585 590
 Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser
 595 600 605
 Asn Thr Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile
 610 615 620
 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu
 625 630 635 640
 Asn Ala Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro
 645 650 655
 Glu Leu Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile
 660 665 670
 Asp Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys
 675 680 685
 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp
 690 695 700
 Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr
 705 710 715 720
 Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr
 725 730 735
 Arg Tyr Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp
 740 745 750
 Phe Asn Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile
 755 760 765
 Asp Asn Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met
 770 775 780
 Lys Lys Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn
 785 790 795 800
 Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr
 805 810 815
 Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu
 820 825 830
 Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile
 835 840 845
 Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser
 850 855

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1644 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- 101 -

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..1644

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

| | |
|---|-----|
| ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT | 48 |
| Met Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn | |
| 1 5 10 15 | |
| AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA | 96 |
| Asn Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg | |
| 20 25 30 | |
| TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA | 144 |
| Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu | |
| 35 40 45 | |
| AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT | 192 |
| Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly | |
| 50 55 60 | |
| ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT | 240 |
| Ile Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn | |
| 65 70 75 80 | |
| ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT | 288 |
| Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe | |
| 85 90 95 | |
| AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT | 336 |
| Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile | |
| 100 105 110 | |
| ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG | 384 |
| Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu | |
| 115 120 125 | |
| TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT | 432 |
| Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn | |
| 130 135 140 | |
| CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA | 480 |
| Pro Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile | |
| 145 150 155 160 | |
| TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT | 528 |
| Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly | |
| 165 170 175 | |
| ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA | 576 |
| Ile Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln | |
| 180 185 190 | |
| ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA | 624 |
| Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu | |
| 195 200 205 | |
| AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA | 672 |
| Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro | |
| 210 215 220 | |

- 102 -

| | |
|--|------|
| GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr 225 230 235 240 | 720 |
| GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe 245 250 255 | 768 |
| TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe 260 265 270 | 816 |
| GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile 275 280 285 | 864 |
| TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn 290 295 300 | 912 |
| AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr 305 310 315 320 | 960 |
| AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335 | 1008 |
| AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350 | 1056 |
| ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA Met-Phe-Gly-Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys 355 360 365 | 1104 |
| ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys 370 375 380 | 1152 |
| AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile 385 390 395 400 | 1200 |
| TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile 405 410 415 | 1248 |
| AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr 420 425 430 | 1296 |
| AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp 435 440 445 | 1344 |
| GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser 450 455 460 | 1392 |
| GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn 465 470 475 480 | 1440 |
| TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp 485 490 495 | 1488 |

- 103 -

| | |
|---|------|
| TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT | 1536 |
| Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr | |
| 500 505 510 | |
| GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA | 1584 |
| Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys | |
| 515 520 525 | |
| AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG | 1632 |
| Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln | |
| 530 535 540 | |
| ACA TTT CCT CTA | 1644 |
| Thr Phe Pro Leu | |
| 545 | |

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 548 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Pro | Val | Thr | Ile | Asn | Asn | Phe | Asn | Tyr | Asn | Asp | Pro | Ile | Asp | Asn |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Asn | Asn | Ile | Ile | Met | Met | Glu | Pro | Pro | Phe | Ala | Arg | Gly | Thr | Gly | Arg |
| | | 20 | | | | | 25 | | | | | | 30 | | |
| Tyr | Tyr | Lys | Ala | Phe | Lys | Ile | Thr | Asp | Arg | Ile | Trp | Ile | Ile | Pro | Glu |
| | | 35 | | | | 40 | | | | | 45 | | | | |
| Arg | Tyr | Thr | Phe | Gly | Tyr | Lys | Pro | Glu | Asp | Phe | Asn | Lys | Ser | Ser | Gly |
| | 50 | | | | 55 | | | | | 60 | | | | | |
| Ile | Phe | Asn | Arg | Asp | Val | Cys | Glu | Tyr | Tyr | Asp | Pro | Asp | Tyr | Leu | Asn |
| 65 | | | 70 | | | | | 75 | | | | | | 80 | |
| Thr | Asn | Asp | Lys | Lys | Asn | Ile | Phe | Leu | Gln | Thr | Met | Ile | Lys | Leu | Phe |
| | | | 85 | | | | | 90 | | | | | | 95 | |
| Asn | Arg | Ile | Lys | Ser | Lys | Pro | Leu | Gly | Glu | Lys | Leu | Leu | Glu | Met | Ile |
| | | 100 | | | | | 105 | | | | | | 110 | | |
| Ile | Asn | Gly | Ile | Pro | Tyr | Leu | Gly | Asp | Arg | Arg | Val | Pro | Leu | Glu | Glu |
| | 115 | | | | | 120 | | | | | 125 | | | | |
| Phe | Asn | Thr | Asn | Ile | Ala | Ser | Val | Thr | Val | Asn | Lys | Leu | Ile | Ser | Asn |
| | 130 | | | | 135 | | | | | 140 | | | | | |
| Pro | Gly | Glu | Val | Glu | Arg | Lys | Lys | Gly | Ile | Phe | Ala | Asn | Leu | Ile | Ile |
| 145 | | | 150 | | | | | 155 | | | | | 160 | | |
| Phe | Gly | Pro | Gly | Pro | Val | Leu | Asn | Glu | Asn | Glu | Thr | Ile | Asp | Ile | Gly |
| | | | 165 | | | | 170 | | | | | | 175 | | |
| Ile | Gln | Asn | His | Phe | Ala | Ser | Arg | Glu | Gly | Phe | Gly | Gly | Ile | Met | Gln |
| | 180 | | | | | | 185 | | | | | | 190 | | |
| Met | Lys | Phe | Cys | Pro | Glu | Tyr | Val | Ser | Val | Phe | Asn | Asn | Val | Gln | Glu |
| | 195 | | | | | 200 | | | | | | 205 | | | |

- 104 -

Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro
 210 215 220
 Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr
 225 230 235 240
 Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe
 245 250 255
 Phe Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe
 260 265 270
 Gly Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile
 275 280 285
 Tyr Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn
 290 295 300
 Lys Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr
 305 310 315 320
 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
 325 330 335
 Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu
 340 345 350
 Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys
 355 360 365
 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys
 370 375 380
 Asn Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile
 385 390 395 400
 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile
 405 410 415
 Asn Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr
 420 425 430
 Lys Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp
 435 440 445
 Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser
 450 455 460
 Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn
 465 470 475 480
 Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp
 485 490 495
 Leu Ile Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr
 500 505 510
 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys
 515 520 525
 Lys Ile Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln
 530 535 540
 Thr Phe Pro Leu
 545

- 105 -

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2616 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2616

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

| | |
|---|-----|
| ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT | 48 |
| Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly | |
| 1 5 10 15 | |
| GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG | 96 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro | |
| 20 25 30 | |
| GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC | 144 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg | |
| 35 40 45 | |
| GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA | 192 |
| Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu | |
| 50 55 60 | |
| GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA | 240 |
| Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr | |
| 65 70 75 80 | |
| GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG | 288 |
| Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu | |
| 85 90 95 | |
| CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC | 336 |
| Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val | |
| 100 105 110 | |
| CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG | 384 |
| Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys | |
| 115 120 125 | |
| GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC | 432 |
| Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr | |
| 130 135 140 | |
| AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT | 480 |
| Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile | |
| 145 150 155 160 | |
| ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG | 528 |
| Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr | |
| 165 170 175 | |
| CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC | 576 |
| Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe | |
| 180 185 190 | |

- 106 -

| | |
|---|------|
| ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205 | 624 |
| GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220 | 672 |
| CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn 225 230 235 240 | 720 |
| CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 | 768 |
| GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 | 816 |
| TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 | 864 |
| AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300 | 912 |
| GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320 | 960 |
| TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 | 1008 |
| AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345 350 | 1056 |
| AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 | 1104 |
| TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr 370 375 380 | 1152 |
| ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 | 1200 |
| TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415 | 1248 |
| AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430 | 1296 |
| GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 | 1344 |
| GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 | 1392 |

- 107 -

| | |
|---|------|
| AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480 | 1440 |
| ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA Ile Thr Ser Asp Thr Asn Ile Glu Ala Glu Glu Asn Ile Ser Leu 485 490 495 | 1488 |
| GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 | 1536 |
| GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu 515 520 525 | 1584 |
| GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540 | 1632 |
| TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu 545 550 555 560 | 1680 |
| CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575 | 1728 |
| TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590 | 1776 |
| AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605 | 1824 |
| CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620 | 1872 |
| GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala 625 630 635 640 | 1920 |
| TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655 | 1968 |
| ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala 660 665 670 | 2016 |
| ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys 675 680 685 | 2064 |
| GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700 | 2112 |
| AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys 705 710 715 720 | 2160 |
| GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 | 2208 |

- 108 -

| | |
|---|------|
| GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn 740 745 750 | 2256 |
| CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp 755 760 765 | 2304 |
| TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile 770 775 780 | 2352 |
| AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800 | 2400 |
| ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 | 2448 |
| GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly 820 825 830 | 2496 |
| CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 | 2544 |
| ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser 850 855 860 | 2592 |
| ACA TTT ACT GAA TAT ATT AAG TAA Thr Phe Thr Glu Tyr Ile Lys * 865 870 | 2616 |

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 872 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

| |
|--|
| Met Gln Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 |
| Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro 20 25 30 |
| Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45 |
| Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 |
| Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80 |
| Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 |
| Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105 110 |

- 109 -

Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Il Asp Thr Glu Leu Lys
 115 120 125
 Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
 130 135 140
 Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
 145 150 155 160
 Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
 165 170 175
 Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
 180 185 190
 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
 195 200 205
 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
 210 215 220
 Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
 225 230 235 240
 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
 245 250 255
 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
 260 265 270
 Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
 275 280 285
 Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
 290 295 300
 Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
 305 310 315 320
 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
 325 330 335
 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
 340 345 350
 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
 355 360 365
 Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
 370 375 380
 Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
 385 390 395 400
 Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
 405 410 415
 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
 420 425 430
 Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
 435 440 445
 Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe
 450 455 460

- 110 -

Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu
 465 470 475 480
 Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu
 485 490 495
 Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro
 500 505 510
 Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu
 515 520 525
 Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu
 530 535 540
 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu
 545 550 555 560
 His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu
 565 570 575
 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys
 580 585 590
 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
 595 600 605
 Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
 610 615 620
 Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala
 625 630 635 640
 Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu
 645 650 655
 Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala
 660 665 670
 Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys
 675 680 685
 Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu
 690 695 700
 Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys
 705 710 715 720
 Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu
 725 730 735
 Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn
 740 745 750
 Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp
 755 760 765
 Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile
 770 775 780
 Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met
 785 790 795 800
 Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys
 805 810 815

- 111 -

Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly
 820 825 830

Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
 835 840 845

Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
 850 855 860

Thr Phe Thr Glu Tyr Ile Lys *
 865 870

(2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2574 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

| | |
|--|------|
| ATGCCGGTTA CCATCAACAA CTTCAACTAC AACGACCCGA TCGACAACAA CAACATCATC | 60 |
| ATGATGGAAC CGCCGTTTCGC ACGTGGTACC GGTCTGTACT ACAAGGCTTT CAAGATCACC | 120 |
| GACCGTATCT GGATCATCCC GGAACGTTAC ACCTTCGGTT ACAAACCTGA GGACTTCAAC | 180 |
| AAGAGTAGCG GGATTTTCAA TCGTGACGTC TCGGAGTACT ATGATCCAGA TTATCTGAAT | 240 |
| ACCAACGATA AGAAGAACAT ATTCCTTCAG ACTATGATCA AGTTATTTAA TAGAATCAAA | 300 |
| TCAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA | 360 |
| GATAGACGTG TTCCACTCGA AGAGTTTAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA | 420 |
| TTAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA | 480 |
| TTTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAATCAT | 540 |
| TTTGCATCAA GGGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTTGCCC AGAATATGTA | 600 |
| AGCGTATTTA ATAATGTTCA AGAAAACAAA GGCGCAAGTA TATTTAATAG ACGTGGATAT | 660 |
| TTTTCAGATC CAGCCTTGAT ATTAATGCAT GAACCTATAC ATGTTTTACA TGGATTATAT | 720 |
| GGCATTAAAG TAGATGATTT ACCAATTGTA CCAATGAAA AAAAATTTT TATGCAATCT | 780 |
| ACAGATGCTA TACAGGCAGA AGAACTATAT ACATTTGGAG GACAAGATCC CAGCATCATA | 840 |
| ACTCCTTCTA CGGATAAAAG TATCTATGAT AAAGTTTTGC AAAATTTTAG AGGGATAGTT | 900 |
| GATAGACTTA ACAAGGTTTT AGTTTGCATA TCAGATCCTA ACATTAATAT TAATATATAT | 960 |
| AAAAATAAAT TTAAAGATAA ATATAAATTC GTTGAAGATT CTGAGGGAAA ATATAGTATA | 1020 |
| GATGTAGAAA GTTTTGATAA ATTATATAAA AGCTTAATGT TTGGTTTTAC AGAAACTAAT | 1080 |
| ATAGCAGAAA ATTATAAAAT AAAAAGTAGA GCTTCTTATT TTAGTGATT CTTACCACCA | 1140 |
| GTAAAAATAA AAAATTTATT AGATAATGAA ATCTATACTA TAGAGGAAGG GTTTAATATA | 1200 |

- 112 -

| | |
|---|------|
| TCTGATAAAG ATATGGAAAA AGAATATAGA GGTCAGAATA AAGCTATAAA TAAACAAGCT | 1260 |
| TATGAAGAAA TTAGCAAGGA GCATTTGGCT GTATATAAGA TACAAATGTG TAAAAGTGTT | 1320 |
| AAAGCTCCAG GAATATGTAT TGATGTTGAT AATGAAGATT TGTCTTTTAT AGCTGATAAA | 1380 |
| AATAGTTTTT CAGATGATTT ATCTAAAAAC GAAAGAATAG AATATAATAC ACAGAGTAAT | 1440 |
| TATATAGAAA ATGACTTCCC TATAAATGAA TTAATTTTAT ATACTGATTT AATAAGTAAA | 1500 |
| ATAGAATTAC CAAGTGAAAA TACAGAATCA CTTACTGATT TTAATGTAGA TGTTCCAGTA | 1560 |
| TATGAAAAAC AACCCGCTAT AAAAAAATT TTTACAGATG AAAATACCAT CTTTCAATAT | 1620 |
| TTATACTCTC AGACATTTC TCTAGATATA AGAGATATAA GTTAAACATC TTCATTTGAT | 1680 |
| GATGCATTAT TATTTTCTAA CAAAGTTTAT TCATTTTTTT CTATGGATTA TATTAAACT | 1740 |
| GCTAATAAAG TGGTAGAAGC AGGATTATTT GCAGGTTGGG TGAAACAGAT AGTAAATGAT | 1800 |
| TTTGTAATCG AAGCTAATAA AAGCAATACT ATGGATAAAA TTGCAGATAT ATCTCTAATT | 1860 |
| GTTCTTATA TAGGATTAGC TTAAATGTA GGAAATGAAA CAGCTAAAGG AAATTTTGAA | 1920 |
| AATGCTTTTG AGATTGCAGG AGCCAGTATT CTACTAGAAT TTATACCAGA ACTTTTAATA | 1980 |
| CCTGTAGTTG GAGCCTTTTT ATTAGAATCA TATATTGACA ATAAAAATAA AATTATTAAA | 2040 |
| ACAATAGATA ATGCTTTAAC TAAAAGAAAT GAAAAATGGA GTGATATGTA CGGATTAATA | 2100 |
| GTAGCGCAAT GGCTCTCAAC AGTTAATACT CAATTTTATA CAATAAAAGA GGAATGTAT | 2160 |
| AAGGCTTTAA ATTATCAAGC ACAAGCATTG GAAGAAATAA TAAAATACAG ATATAATATA | 2220 |
| TATTCTGAAA AAGAAAAGTC AAATATTAAC ATCGATTTTA ATGATATAAA TTCTAACTT | 2280 |
| AATGAGGGTA TTAACCAAGC TATAGATAAT ATAAATAATT TTATAAATGG ATGTTCTGTA | 2340 |
| TCATATTTAA TGAAAAAAT GATTCCATTA GCTGTAGAAA AATTACTAGA CTTTGATAAT | 2400 |
| ACTCTCAAAA AAAATTTGTT AAATTATATA GATGAAAATA AATTATATTT GATTGGAAGT | 2460 |
| GCAGAATATG AAAAATCAAA AGTAAATAAA TACTTGAAAA CCATTATGCC GTTTGATCTT | 2520 |
| TCAATATATA CCAATGATAC AATACTAATA GAAATGTTTA ATAAATATAA TAGC | 2574 |

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2574 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

| | |
|---|-----|
| ATGCCAGTTA CAATAAATAA TTTAATTAT AATGATCCTA TTGATAATAA TAATATTATT | 60 |
| ATGATGGAGC CTCCATTGTC GAGAGGTACG GGGAGATATT ATAAAGCTTT TAAATCACA | 120 |
| GATCGTATTT GGATAATACC GGAAAGATAT ACTTTTGGAT ATAAACCTGA GGATTTTAAT | 180 |
| AAAAGTCCG GTATTTTAA TAGAGATGTT TGTGAATATT ATGATCCAGA TTACTTAAAT | 240 |

- 113 -

| | |
|--|------|
| ACTAATGATA AAAAGAATAT ATTTTACAA ACAATGATCA AGTTATTAA TAGAATCAAA | 300 |
| TCAAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA | 360 |
| GATAGACGTG TTCCACTCGA AGAGTTTAAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA | 420 |
| TTAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA | 480 |
| TTTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAATCAT | 540 |
| TTTGCATCAA GGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTGGCC AGAATATGTA | 600 |
| AGCGTATTTA ATAATGTTCA AGAAAACAAA GCGCAAGTA TATTTAATAG ACGTGGATAT | 660 |
| TTTTCAGATC CAGCCTTGAT ATTAATGCAT GAACTCATCC ACGTCCTCCA CGGTCTCTAC | 720 |
| GGTATCAAAG TAGACGACCT CCCGATCGTC CCGAACGAAA AAAAATTCTT CATGCAGAGC | 780 |
| ACCGACGCAA TCCAGGCAGA AGAACTCTAC ACCTTCGGTG GTCAGGACCC GAGCATCATC | 840 |
| ACCCCGAGCA CCGACAAAAG CATCTACGAC AAAGTCCTCC AGAACTCCG TGGTATCGTC | 900 |
| GACCGTCTCA ACAAAGTCCT CGTCTGCATC AGCGACCCGA ACATCAACAT CAACATCTAC | 960 |
| AAAAACAAAT TCAAAGACAA ATACAAATTC GTCGAAGACA GCGAAGGTAA ATACAGCATC | 1020 |
| GACGTCGAGA GCTTCGACAA ACTCTACAAA AGCCTCATGT TCGGTTTCAC CGAAACCAAC | 1080 |
| ATCGCAGAAA ACTACAAAT CAAAACCCGT GCAAGCTACT TCAGCGACAG CCTCCCGCCG | 1140 |
| GTCAAAATCA AAAACCTCCT CGACAACGAA ATCTACACCA TCGAAGAAGG TTTCAACATC | 1200 |
| AGCGACAAAG ACATGGAAAA AGAATACCGT GGTCAGAACA AAGCAATCAA CAAACAAGCT | 1260 |
| TACGAAGAAA TCAGCAAAGA ACACCTCGCA GTCTACAAAA TCCAGATGTG CAAAAGCGTC | 1320 |
| AAAGCACCGG GTATCTGCAT CGACGTTGAC AACGAAGACC TCTTCTTCAT CGCAGACAAA | 1380 |
| AACAGCTTCA GCGACGACCT CAGCAAAAAC GAACGTATCG AATACAACAC CCAGAGCAAC | 1440 |
| TACATCGAAA ACGACTTCCC GATCAACGAA CTCATCCTCG ACACCGACCT CATCAGCAAA | 1500 |
| ATCGAACTCC CGAGCGAAAA CACCGAAAGC CTCACCGACT TCAACGTTGA CGTCCCGGTC | 1560 |
| TACGAAAAAC AGCCGGCAAT CAAAAAATC TTCACCGACG AAAACACCAT CTTCCAGTAC | 1620 |
| CTCTACAGCC AGACCTTCCC GCTAGATATA AGAGATATAA GTTTAACATC TTCATTTGAT | 1680 |
| GATGCATTAT TATTTTCTAA CAAAGTTTAT TCATTTTTTT CTATGGATTA TATTAAACT | 1740 |
| GCTAATAAAG TGGTAGAAGC AGGATTATTT GCAGGTGGG TGAAACAGAT AGTAAATGAT | 1800 |
| TTTGTAATCG AAGCTAATAA AAGCAATACT ATGGATAAAA TTGCAGATAT ATCTCTAATT | 1860 |
| GTTCCTTATA TAGGATTAGC TTAAATGTA GGAAATGAAA CAGCTAAAGG AAATTTTGAA | 1920 |
| AATGCTTTTG AGATTGCAGG AGCCAGTATT CTACTAGAAT TTATACCAGA ACTTTTAATA | 1980 |
| CCTGTAGTTG GAGCCTTTTT ATTAGAATCA TATATTGACA ATAAAAATAA AATTATTAAA | 2040 |
| ACAATAGATA ATGCTTTAAC TAAAGAAAT GAAAAATGGA GTGATATGTA CGGATTAATA | 2100 |
| GTAGCGCAAT GGCTCTCAAC AGTTAATACT CAATTTTATA CAATAAAGA GGGAATGTAT | 2160 |
| AAGGCTTTAA ATTATCAAGC ACAAGCATTG GAAGAAATAA TAAATACAG ATATAATATA | 2220 |
| TATTCTGAAA AAGAAAAGTC AAATATTAAC ATCGATTTTA ATGATATAAA TTCTAACTT | 2280 |

- 114 -

| | |
|---|------|
| AATGAGGGTA TTAACCAAGC TATAGATAAT ATAAATAATT TTATAAATGG ATGTTCTGTA | 2340 |
| TCATATTTAA TGAAAAAAT GATTCCATTA GCTGTAGAAA AATTACTAGA CTTTGATAAT | 2400 |
| ACTCTCAAAA AAAATTTGTT AAATTATATA GATGAAAATA AATTATATTT GATTGGAAGT | 2460 |
| GCAGAATATG AAAAATCAAA AGTAAATAAA TACTTGAAAA CCATTATGCC CTTTGATCTT | 2520 |
| TCAATATATA CCAATGATAC AATACTAATA GAAATGTTTA ATAAATATAA TAGC | 2574 |

CLAIMS

1. A polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and wherein said second domain is adapted (i) to translocate the polypeptide into a cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into a cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of clostridial neurotoxin precursor that can be converted into toxin by proteolytic action.
2. A polypeptide according to Claim 1 wherein said first domain comprises a clostridial toxin light chain.
3. A polypeptide according to Claim 1 wherein said first domain comprises a fragment or variant of a clostridial toxin light chain.
4. A polypeptide according to Claim 2 or 3 wherein the clostridial toxin is a botulinum toxin.
5. A polypeptide according to any preceding claim wherein the first domain exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin.
6. A polypeptide according to any preceding claim wherein said second domain comprises a clostridial toxin heavy chain H_N portion.
7. A polypeptide according to any of Claims 1-5 wherein said second domain comprises a fragment or variant of a clostridial toxin heavy chain H_N portion.
8. A polypeptide according to Claim 6 or 7 wherein the clostridial toxin is a

- 116 -

botulinum toxin.

9. A polypeptide according to any of Claims 1-8 further comprising a third domain adapted for binding of the polypeptide to a cell, by binding of the third domain directly to a cell or by binding of the third domain to a ligand or to ligands that bind to a cell.
10. A polypeptide according to Claim 9 wherein said third domain is for binding the polypeptide to an immunoglobulin.
11. A polypeptide according to Claim 10 wherein said third domain is a tandem repeat synthetic IgG binding domain derived from domain β of Staphylococcal protein A.
12. A polypeptide according to Claim 9 wherein said third domain comprises an amino acid sequence that binds to a cell surface receptor.
13. A polypeptide according to Claim 12 wherein said third domain is insulin-like growth factor-1 (IGF-1).
14. A polypeptide according to any preceding claim comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and a portion designated H_N of a botulinum toxin heavy chain.
15. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type A.
16. A polypeptide according to Claim 15 wherein the botulinum toxin type A light chain variant has at residue 2 a glutamate, at residue 26 a lysine and at residue 27 a tyrosine.

- 117 -

17. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type B.
18. A polypeptide according to any of Claims 1-13 comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and at least 100 N-terminal amino acids of a botulinum toxin heavy chain.
19. A polypeptide according to Claim 18 comprising a botulinum toxin type B light chain, or a fragment or variant thereof, and 107 N-terminal amino acids of a botulinum toxin type B heavy chain.
20. A polypeptide according to Claim 15 or 16 comprising at least 423 of the N-terminal amino acids of botulinum toxin type A heavy chain.
21. A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain and 423 N-terminal amino acids of a botulinum toxin type A heavy chain.
22. A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain variant wherein residue 2 is a glutamate, residue 26 is a lysine and residue 27 is a tyrosine, and 423 N-terminal amino acids of a botulinum toxin type A heavy chain.
23. A polypeptide according to Claim 17 comprising at least 417 of the N-terminal amino acids of botulinum toxin type B heavy chain.
24. A polypeptide according to Claim 23 comprising a botulinum toxin type B light chain and 417 N-terminal amino acids of a botulinum toxin type B heavy chain.
25. A polypeptide according to any of Claims 14-24 lacking a portion designated

H_C of a botulinum toxin heavy chain.

26. A polypeptide comprising a botulinum toxin light chain and a fragment of a botulinum toxin heavy chain, said fragment being not capable of binding to cell surface receptors.

27. A polypeptide according to Claim 26 lacking an intact portion designated H_C of a botulinum toxin heavy chain.

28. A polypeptide according to any preceding claim comprising a variant of a clostridial toxin and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin.

29. A polypeptide according to Claim 28 comprising a variant of a clostridial toxin light chain and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin light chain.

30. A polypeptide according to Claim 28 or 29 comprising a variant of a clostridial toxin heavy chain H_N portion and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin heavy chain H_N portion.

31. A polypeptide according to Claim 28, 29 or 30 obtainable by modification of a DNA encoding the polypeptide so as to introduce one or more nucleotide coding for the cleavage site.

32. A fusion protein comprising a fusion of (a) a polypeptide according to any of Claims 1-31 with (b) a second polypeptide being a polypeptide or oligopeptide adapted for binding to an affinity matrix so as to enable purification of the fusion protein using said matrix.

33. A fusion protein according to Claim 32 wherein said second polypeptide is

- 119 -

adapted to bind to a chromatography column, such as an affinity matrix of glutathione Sepharose.

34. A fusion protein according to Claim 32 or 33 wherein a specific protease cleavage site is incorporated between the first and second polypeptides, said protease site enabling proteolytic separation of first and second polypeptides.

35. A composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the botulinum toxin, said derivative further being non-toxic *in vivo* due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic *in vivo*.

36. A composition according to Claim 35 or a polypeptide according to any of Claims 1-31 or a fusion protein according to Claim 32, 33 or 34 for use as a positive control in a toxin assay.

37. A composition according to Claim 35 or a polypeptide according to any of Claims 1-31 or a fusion protein according to Claim 32, 33 or 34 for use as a vaccine against clostridial toxin.

38. A composition according to Claim 35 or a polypeptide according to any of Claims 1-31 or a fusion protein according to Claim 32, 33 or 34 for *in vivo* use.

39. A pharmaceutical composition comprising a composition according to Claim 35, a polypeptide according to any of claims 1-31 or a fusion protein according to Claim 32, 33 or 34, in combination with a pharmaceutically acceptable carrier.

40. A nucleic acid encoding a polypeptide or a fusion protein according to any of Claims 1-34.

41. A nucleic acid encoding a polypeptide or a fusion protein according to Claim

- 120 -

40 and comprising nucleotides encoding residues 1-448 of a botulinum toxin type A light chain.

42. A nucleic acid according to Claim 40 or 41 comprising nucleotides encoding residues 1-423 of a botulinum toxin type A heavy chain H_N domain.

43. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 and comprising nucleotides encoding residues 1-470 of a botulinum toxin type B light chain.

44. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 or 43 comprising nucleotides encoding residues 1-417 of a botulinum toxin type B heavy chain H_N domain.

45. A nucleic acid according to any of Claims 40-44 comprising nucleotides encoding a restriction endonuclease cleavage site not present in native clostridial toxin sequence.

46. A nucleotide according to Claim 45 obtainable by modification of a nucleotide encoding a polypeptide or fusion protein according to any of claims 1-34 so as to introduce said cleavage site.

47. A DNA according to any of claims 40-46.

48. A DNA selected from SEQ ID No:s 1, 8, 10, 12, 14, 16, 18, 23 and 24.

49. A method of manufacture of a polypeptide according to any of Claims 1-31 comprising expressing in a host cell a nucleic acid according to any of Claims 40-48 and recovering the polypeptide.

50. A method of manufacture of a polypeptide according to any of Claims 1-31 comprising expressing in a host cell a nucleic acid encoding a fusion protein

- 121 -

according to Claim 32, 33 or 34, purifying the fusion protein by eluting the fusion protein through an affinity matrix adapted to retain the fusion protein and eluting through said matrix a ligand adapted to displace the fusion protein, and recovering the fusion protein.

51. A method of manufacture according to Claims 49 or 50 in which the nucleic acid is DNA.

52. A cell expressing a polypeptide or fusion protein according to any of Claims 1-34.

1/11




FIG. 1

2 / 11




FIG. 2

3 / 11




FIG. 3

LH_{423/A} M Q F V N K Q F N Y K D P V N G V D I A Y I K I P N A G Q M Q P V (Seq I.D. 2)

G S P G I H M T S T R L Q K L L E F E L P

²³LH_{423/A}
(Q₂E, N₂₆K, A₂₇Y)

G T M E F V N K Q F N Y K D P V N G V D I A Y I K I P K Y G Q M Q P V (Seq I.D. 4)

²LH_{423/A}
(Q₂E, N₂₆K, A₂₇Y)

G S M E F V N K Q F N Y K D P V N G V D I A Y I K I P K Y G Q M Q P V (Seq I.D. 6)

Native BoNT/A,
C. botulinum 2169
Thompson et al. 1990

M Q F V N K Q F N Y K D P V N G V D I A Y I K I P N A G Q M Q P V

Native BoNT/A,
C. botulinum 62A
Binz et al. 1990

M P F V N K Q F N Y K D P V N G V D I A Y I K I P N A G Q M Q P V

 = REGIONS OF NON-IDENTITY WITH THE NATIVE SEQUENCES.

FIG. 4

5 / 11




FIG. 5




FIG. 6

6/11

IGF-1

2587/863 TAC GTA GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG CCT GGA
Y V D N Q R L L L S T F T E Y I K S R P G

2647/883 CCG GAG ACG CTC TGC GGG GCT GAG CTG GTG GAT GCT CTT CAG TTC GTG TGT GGA GAC AGG
P E T L C G A E L V D A L Q F V C G D R

2707/903 GGC TTT TAT TTC AAC AAG CCC ACA GGG TAT GGC TCC AGC AGT CGG AGG GCG CCT CAG ACA
G F Y F N K P T G Y G S S S R A P Q T

2767/923 GGT ATC GTG GAT GAG TGC TGC TTC CGG AGC TGT GAT CTA AGG AGG CTG GAG ATG TAT TGC
G I V D E C C F R S C D L R R L E M Y C

2827/943 GCA CCC CTC AAG CCT GCC AAG TCA GCT GAA GCT TAG
A P L K P A K S A E A stop

FIG. 7

CtxA14

2587/863 TAC GTA GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG CCT CAA
Y V D N Q R L L L S T F T E Y I K S R P Q

2647/883 TCT AAA GTT AAA AGA CAA ATA TTT TCA GGC TAT CAA TCT GAT ATT GAT ACA CAT AAT AGA
S K V K R Q I F S G Y Q S D I D T H N R

2707/903 ATT AAG GAT GAA TTA TGA
I K D E L stop

FIG. 8

7/11

2587/863 TAC GTA GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT 2617/873 GAA TAT ATT AAG TCA GGC CTG AAT
 Y V D N Q R L L S T F T E Y I K S G L N
 2647/883 TCC CCG GGT GCA GCT CAT TAT GCG CAA CAC GAT GAA GCC GTA GAC AAC AAA TTC AAC AAA
 S P G A A H Y A Q H D E A V D N K F N K
 2707/903 GAA CAA CAA AAC GCG TTC TAT TAT GAG ATC TTA CAT TTA CCT AAC TTA AAC GAA GAA CAA CGA
 E Q Q N A F Y E I L H L P N L N E E Q R
 2767/923 AAC GCC TTC ATC CAA AGT TTA AAA GAT GAC CCA AGC CAA AGC GCT AAC CTT TTA GCA GAA
 N A F I Q S L K D D P S Q S A N L L A E
 2827/943 GCT AAA AAG CTA AAT GAT GCT CAG GCG CCG AAA GTA GAC AAC AAC AAA GAA GAA CAA
 A K K L N D A Q A P K V D N K F N K E Q
 2887/963 CAA AAC GCG TTC TAT GAG ATC TTA CAT TTA CCT AAC TTA AAC GAA GAA CAA CGA AAC GCC
 Q N A F Y E I L H L P N L N E E Q R N A
 2947/983 TTC ATC CAA AGT TTA AAA GAT GAC CCA AGC CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA
 F I Q S L K D D P S Q S A N L L A E A K
 3007/1003 AAG CTA AAT GAT GCT CAG CCG CCG AAA GTA GAC TAG 3037/1013
 K L N D A Q A P K V D *

FIG. 9




FIG. 10


LH₄₂₃/A^{9/11}

FIG. 11

10/11




FIG. 12

11 / 11




FIG. 13

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02273

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/31 C12N1/21 C12P21/02 C07K14/33 A61K38/16
A61K39/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | WO 96 12802 A (OPHIDIAN PHARM INC ; WILLIAMS JAMES A (US); PADHYE NISHA V (US); KI) 2 May 1996 see the whole document --- | 1-52 |
| X | KURAZONO H ET AL: "Minimal essential *domains* specifying toxicity of the *light* *chains* of tetanus toxin and botulinum neurotoxin type A." J BIOL CHEM, JUL 25 1992, 267 (21) P14721-9, UNITED STATES, XP002047910 see table II --- -/-- | 1-52 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex:

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

9 December 1997

Date of mailing of the international search report

30. 01. 98

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hillenbrand, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02273

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | <p>LI ET AL: "A SINGLE MUTATION IN THE RECOMBINANT LIGHT CHAIN OF TETANUS TOXIN ABOLISHES ITS PROTEOLYTIC ACTIVITY AND REMOVES THE TOXICITY SEEN AFTER RECONSTITUTION WITH NATIVE HEAVY CHAIN" BIOCHEMISTRY, vol. 33, no. 22, 1994, pages 7014-7020, XP002015938 see the whole document</p> <p style="text-align: center;">---</p> | 1 |
| A | <p>BINZ T ET AL: "THE COMPLETE SEQUENCE OF BOTULINUM NEUROTOXIN TYPE A AND COMPARISON WITH OTHER CLOSTRIDIAL NEUROTOXINS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 16, 5 June 1990, pages 9153-9158, XP002009348 see the whole document</p> <p style="text-align: center;">-----</p> | 1,26,35 |

INTERNATIONAL SEARCH REPORT

Int'l. .onal Application No

PCT/GB 97/02273

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9612802 A | 02-05-96 | US 5601823 A | 11-02-97 |
| | | US 5196193 A | 23-03-93 |
| | | AU 3968395 A | 15-05-96 |
| | | EP 0796326 A | 24-09-97 |
| | | FI 971732 A | 23-06-97 |
| | | NO 971868 A | 24-06-97 |
| | | PL 320214 A | 15-09-97 |
| | | ZA 9508990 A | 15-05-96 |
| | | AU 6653894 A | 04-07-94 |
| | | CA 2150935 A | 23-06-94 |
| | | EP 0671902 A | 20-09-95 |
| | | WO 9413264 A | 23-06-94 |
| | | US 5466672 A | 14-11-95 |
| | | US 5599539 A | 04-02-97 |
| | | AU 638786 B | 08-07-93 |
| | | AU 6895191 A | 31-05-91 |
| | | EP 0498854 A | 19-08-92 |
| | | WO 9106306 A | 16-05-91 |
| | | US 5443976 A | 22-08-95 |
| | | US 5340923 A | 23-08-94 |